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The D1R and D2R dopamine receptor (DAR) subtypes represent the two most 
abundant and highly targeted DARs, but the precise mechanisms of drug action at the 
molecular level are not well understood. A revolution in the understanding of G protein-
coupled receptors depicts receptors as dynamic, conformationally fluid proteins. This led 
to the idea that receptor heteromerization or ligand binding can promote functionally 
selective/biased signaling. In this vein, two aspects of DAR signaling are studied: D1R-
D2R heteromerization and biased D2R signaling. 
In Chapter 2, the pharmacology and signaling mechanism for the D1R-D2R 
heteromer is investigated. Diverging from canonical D1R-Gs/olf protein and D2R-Gi/o 
protein coupling, the D1R-D2R heteromer was proposed to couple to Gq protein-
mediated Ca2+ mobilization. In Chapter 2, it is shown that D1R-D2R-mediated Ca2+ 
signaling may not be completely Gq protein-dependent or heteromer-specific, and may 
largely depend on Gi/o protein, Gs/olf protein, and Gβγ signaling. Furthermore, SKF83959 
(previously reported as a D1R-D2R selective agonist) has significant cross-reactivity to 
other receptors, warranting careful interpretation of its use in vivo. 
In Chapter 3, a high-throughput screen was conducted to interrogate a small-
molecule library for novel D2R agonists using a Ca2+ mobilization assay. Following 
additional orthogonal screening of cAMP modulation and β-arrestin-2 recruitment, a G 
protein biased D2R agonist was identified (MLS1547). MLS1547 analogs were tested 
using the cAMP accumulation and β-arrestin-2 recruitment assays. These results provided 
the basis for pharmacophore modeling and molecular docking analyses to build structure-




Chapter 4 extends the pharmacological profiling of MLS1547 by showing that 
MLS1547 stimulates a low but significant degree of D2R internalization. The 
pharmacophore model is also confirmed and extended by testing additional MLS1547 
analogs and developing a refined SAR. 
In Chapter 5, another high-throughput screen was conducted to detect β-arrestin-2 
biased D2R selective ligands. Although one β-arrestin-2 biased agonist was identified, 
further testing was not possible, as a source for the compound was not available.  
 Taken together, these data expand the understanding of the spectrum of signaling 
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Chapter 1: Background and Significance 
Dopamine Receptor Structure 
Dopamine receptors (DAR) are class A (rhodopsin family), seven transmembrane, 
G protein-coupled receptors (GPCRs), of which five genes exist in mammals. Each gene 
encodes a DAR subtype (D1R - D5R), which are grouped by structure, pharmacology, 
and function into the D1-like (D1R1–3 and D5R4,5) and D2-like (D2R6–8, D3R9, and 
D4R10,11) DAR sub-families.  
When comparing the DARs, the highest degree of sequence homology exists 
within the transmembrane (TM) spanning domains, where the endogenous ligand 
dopamine (DA) binds. The D1R and D5R share 80% homology (Figure 1) in the TM 
domains while the D2R shares 75% and 53% TM sequence homology with the D3R and 
D4R (Figure 2), respectively12. The protein sequences diverge much more outside of the 
transmembrane domains, making them prime targets for the development of subtype 
selective allosteric ligands. Notably, the D2R also exists as two protein isoforms: D2R 
long (D2LR) and D2R short (D2SR). Post-transcriptional mRNA splicing results in the 
excision of 29 amino acids in the third intracellular loop of the receptor to form D2SR 
(Figure 2).  
 One of the best approaches for understanding receptor structure and function is to 
have a crystal structure or other atomic level view of the receptor (e.g. via protein NMR 
or cryo-electron microscopy). However, crystallization of GPCRs is generally very 
difficult due to their low abundance and hydrophobicity. Accordingly, of the five DAR 
subtypes, only the D3R has been successfully crystallized (PDB: 3PBL)13. Despite this 
limitation, the crystal structure of the D3R can provide insight to the structure of other 
DARs, and using the known structures of other class A GPCRs, pharmacological 
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structure-activity relationships, and mutational analyses, models with predictive value 
can be developed, suggesting how proteins and ligands interact with the receptor (see 
Chapter 3 and Figure 26). 
 
 
Figure 1: Amino acid sequence of the human D1R.  
The membrane domain is depicted as a pink box. Residues unique to the D1R are shown in blue while 




Dopamine and Dopamine Receptor Expression and Function in Brain 
Of the five DARs, the D1R is the most widely expressed subtype. It is expressed 
primarily in the striatum, nucleus accumbens (NAc), and olfactory tubercle, with lower 
levels in the cerebral cortex, hypothalamus, and thalamus14,15. The D2R is the second 
most highly expressed DAR in the brain, and like the D1R, the D2R is most highly 
expressed in the striatum, NAc, and olfactory tubercle, but it is also expressed in the 
substantia nigra (SN) and ventral tegmental area (VTA)14–17. The D2LR isoform is more 
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Figure 2: Amino acid sequence of the human D2LR. 
The membrane domain is depicted as a pink box. Residues unique to the D2R are shown in blue. The 
black bar running parallel to the third intracellular loop indicates the 29 residues spliced out to form the 
D2SR. Residues shared between the D2R and D3R are highlighted in yellow. Residues shared between 
the D2R and D4R are highlighted in green. Residues common between the D2R, D3R, and D4R are 
highlighted in magenta. 
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striatum18,19. On the other hand, the D2SR is thought to function primarily as an 
autoreceptor, and has its strongest expression in the cell bodies and axons of 
dopaminergic neurons of the primary midbrain20.  
Expressed at a much lower level and the D1R and D2R are the D3R, D4R, and 
D5R. The D3R is particularly expressed in the ventral striatum, SN, VTA, hippocampus, 
septal area, and cortical areas12. The D4R is expressed at the lowest level compared to the 
other DARs, with expression in the frontal cortex, amygdala, hippocampus, 
hypothalamus, globus pallidus, SN, and thalamus12. The D5R is expressed mostly in the 
hippocampus and hypothalamus21–23. 
Within the brain, DA generally functions as a modulatory neurotransmitter that 
modulates the effects of glutamate and GABA signaling. Relatively few DA-producing 
(dopaminergic) neurons exist, with estimates ranging from 400,000 to 600,000 
dopaminergic neurons in the human brain24,25. These neurons project from three major 
nuclei and release DA to large parts of the brain through four dopaminergic pathways 
(Figure 1): 
1. Nigrostriatal pathway: dopaminergic neurons project from the SN pars compacta 
to the dorsal striatum, mainly targeting the GABAergic medium spiny neurons 
(MSN).  
2. Mesolimbic pathway: dopaminergic neurons project from the VTA to the ventral 
striatum (NAc and olfactory tubercle). Again, the dopaminergic neurons mainly 
target GABAergic MSNs.  
3. Mesocortical pathway: dopaminergic neurons project from the VTA to the 
cerebral cortex.  
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4. Tuberoinfundibular pathway: dopaminergic neurons project from the arcuate 
nucleus of the hypothalamus to the median eminence of the pituitary gland. 
These pathways collectively regulate movement, reward, reinforcement, cognitive 
function, memory, and sleep26–28, and dysfunction of dopaminergic systems may be 
involved in neuropsychiatric disorders such as schizophrenia, attention deficit 
hyperactivity disorder (ADHD), Parkinson’s disease, and depression29–31. 
 
Dopamine Receptor-mediated G Protein Signaling 
The DARs primarily couple to, and signal through, heterotrimeric G proteins. 
These G proteins are GTPases which consist of a G subunit, a Gβ subunit, and a Gγ 
 
Figure 3: Diagram of the four main dopaminergic pathways.  
Dopaminergic neurons project from three main nuclei (grey patches): the substantia nigra (SN), ventral 
tegmental area (VTA), and arcuate nucleus (AN) of the hypothalamus. Projections from these nuclei 
follow four distinct physiological pathways. The nigrostriatal pathway runs from the SN to the dorsal 
striatum (green). The mesolimbic pathway runs from the VTA to the nucleus accumbens (NAc, blue). 
The mesocortical pathway runs from the VTA to the prefrontal cortex (PFC, red). The 
tuberoinfundibular pathway runs from the AN to the median eminence of the pituitary gland (ME, teal). 
Added text and arrows to figure from Creative Commons source: Patrick J. Lynch; illustrator; C. Carl 
Jaffe; MD; cardiologist Yale University Center for Advanced Instructional Media Medical Illustrations 
by Patrick Lynch, generated for multimedia teaching projects by the Yale University School of 
Medicine, Center for Advanced Instructional Media, 1987-2000. Patrick J. Lynch, 
http://patricklynch.net Creative Commons. 
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subunit. In its inactive state, the heterotrimeric G protein is bound to GDP. When 
activated by a receptor, the GDP is replaced with GTP, and the G subunit dissociates 
from the Gβγ subunits to initiate signaling. Four main types of heterotrimeric G proteins 
are expressed in the brain32–34: adenylate cyclase inhibiting (Gi and Go proteins), 
adenylate cyclase stimulating (Gs and Golf proteins), phospholipase C β (PLCβ) 
stimulating (Gq and G11 proteins), and Rho family G proteins (G12 and G13 proteins).  
Canonically, the D1-like receptors couple to the stimulatory Gs/olf proteins to 
activate adenylate cyclase-mediated formation of cAMP while the D2-like receptors 
couple to the inhibitory Gi/o proteins to inhibit adenylate cyclase
12,35 (Figure 4, Figure 5). 
Following activation, the D1-like receptor-mediated cAMP production causes the 
activation of protein kinase A (PKA), while D2-like receptor-mediated inhibition of 
cAMP production causes inactivation of PKA. PKA primarily works to modulate 
downstream protein activity and transcription, and one of its most well studied targets is 
the 32-kDa DA and cAMP-regulated phosphoprotein (DARPP-32), which is targeted by 
many other cellular proteins, and serves to combine multiple signaling inputs into one 
output36. Activation of DARPP-32 by the D1R and D5R causes enhancement of the 
NMDA receptor (NMDAR) signaling37, which is important for synaptic plasticity, and 
has a role in learning and memory. This enhancement can by countered by the D2R, 
which inhibits the production of cAMP, hence decreasing PKA and subsequent DARPP-




There is some evidence that DARs can also couple to non-canonical signaling 
cascades. The D1-like and D2-like receptors can activate the Gq protein
39–42 (Figure 4) 
and stimulate Gβγ release
42–44 (Figure 5) to activate PLCβ. The activation of PLCβ leads 
to the production of diacylglycerol and inositol triphosphate. Both second messengers 
lead ultimately to a change in long-term neural plasticity. D2-like receptor-mediated 
activation of the Gβγ subunits is not limited to PLCβ activation and has been shown to 
lead to signaling through ion channels. More specifically, the D2R and D3R can activate 
the G protein-coupled inwardly-rectifying K+ channel (GIRK)45,46. The D2R is also able 
to inhibit L/N-type Ca2+ channels44,47. Additionally, it has been suggested that a D1R-
 
Figure 4: D1-like dopamine receptor signaling pathways. 
Green arrows indicate activation, red lines indicate inhibition, and black arrows indicate an interaction 
that can be stimulatory or inhibitory depending on the cellular context. Abbreviations: DAG 
(diacylglycerol), DARPP-32 (32-kDa dopamine and cAMP-regulated phosphoprotein), ERK 
(extracellular signal-regulated kinase 1/2), MEK (MEK/ERK kinase), IP3 (inositol triphosphate), 
NMDAR (NMDA receptor), PKC (protein kinase C), PKA (protein kinase A), PP1 (protein 




D2R heteromer is able to form in vitro and couple to the Gq protein to activate PLCβ-
mediated Ca2+ response (see Figure 4 and Chapter 2 for more details)42,48.  
 
Regulation of DAR Signaling: G Protein-coupled Receptor Kinases and β-
arrestins 
Following activation, the DARs undergo rapid desensitization and internalization 
to regulate signaling activity. Desensitization involves the separation of the activated 
DAR from the G protein. This begins when a G protein-coupled receptor kinase (GRK) 
phosphorylates intracellular residues on the DAR49,50. Seven GRKs exist which are 
subdivided into the GRK1-like subfamily (GRK1 and GRK7), GRK2-like subfamily 
(GRK2 and GRK3), and GRK4-like subfamily (GRK4, GRK5, and GRK6)49. GRK1 and 
GRK7 are limited to regulating visual opsins and GRK4 has limited expression in the 
cerebellum, kidney, and testis51, and has been shown to only regulate DAR function in 
 
 
Figure 5: D2-like dopamine receptor signaling pathways.  
Green arrows indicate activation, red lines indicate inhibition, and black arrows indicate an interaction 
that can be stimulatory or inhibitory depending on the cellular context. Abbreviations: DAG 
(diacylglycerol), DARPP-32 (32-kDa dopamine and cAMP-regulated phosphoprotein), IP3 (inositol 
triphosphate), NMDAR (NMDA receptor), PKC (protein kinase C), PKA (protein kinase A), PP1 
(protein phosphatase), PP2B (protein phosphatase 2B/calcineurin). 
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the kidney52. The GRK2, GRK3, GRK5, and GRK6 are more widely expressed and have 
all been associated with DAR regulation using in vitro, in vivo, and behavioral studies27. 
However, it is not known if a single GRK subtype regulates a single DAR subtype, and it 
is more likely that specific GRK-DAR interactions are tissue dependent.  
Following GRK-mediated DAR phosphorylation, the scaffolding protein arrestin 
binds to the receptor, although it should be noted that, in some cases such as with the 
D2R, the phosphorylation event itself is not required for arrestin recruitment53,54. Arrestin 
binding promotes receptor desensitization by physically blocking the binding of G 
proteins to the receptor. Arrestin subsequently recruits the clathrin-binding AP2 
protein55–57 which promotes the formation of clathrin-coated pits, resulting in receptor 
endocytosis53,58,59.  
The arrestins are classified into two groups: the visual arrestins (arrestin 1 and 
arrestin 4) which are expressed in rod and cone cells of the eye, and the non-visual 
arrestins (arrestin 2 and arrestin 3, a.k.a. β-arrestin-1 and β-arrestin-2, respectively) which 
are ubiquitously expressed60,61. Although there is some evidence that β-arrestin-1 may 
interact with the DARs in the brain62–64, this interaction has not been shown to regulate G 
protein-mediated DAR signaling. Instead, based on a variety of studies, β-arrestin-2 has 
been shown to be the primary regulator of DAR signaling in the brain27. Interestingly, it 
has been proposed that the sequence of residues that GRK phosphorylates on the receptor 
may regulate how arrestin functions following receptor binding65,66 and may determine 
whether the receptor is recycled or degraded67. Furthermore, it has been reported that 
some GPCRs exhibit arrestin-independent mechanisms of receptor internalization49 that 
10 
 
are largely dependent on the clathrin adaptor AP268 and various GRKs68–75. Thus far, no 
arrestin-independent internalization mechanisms have been reported for the DARs.  
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Chapter 2: D1R-D2R Synergy Promotes Ca2+ Signaling via Multiple 
Mechanisms 
Background 
Before the D1R-D2R heteromer was proposed, the subject of D1R and D2R 
cellular colocalization was, and still is, debatable. Most investigations of potential D1R 
and D2R cellular co-expression have been performed within the striatum, where over 
90% of the neurons are MSNs. MSNs 
modulate cortical signals through two 
neuronal pathways that are defined by gene 
expression profiles and function (Figure 6). 
In the “direct” (striatonigral) pathway, 
MSN axons project towards and inhibit 
activity in the substantia nigra, allowing a 
net excitation of the motor cortex via the 
thalamus. In the “indirect” (striatopallidal) 
pathway, the striatum inhibits the activity of 
the globus pallidus. This allows the 
subthalamic nucleus to fire, resulting in net inhibition of the motor cortex. MSNs which 
form the direct pathway co-express D1R along with the neuropeptides dynorphin and 
substance P, while the MSNs of the indirect pathway co-express D2R and the 
neuropeptide enkephalin76.  
Although there is evidence for concurrent expression of D1R and D2R in several 
brain regions, co-expression within the same neurons has been a matter of much debate. 
Immunolabeling of receptor proteins in striatal neural slices visualized by electron 
 
Figure 6: Connectivity diagram of the 
striatonigral and striatopalladial pathways.  
Excitatory glutamatergic pathways in green, 
inhibitory GABAergic pathways in red, and 
modulatory dopaminergic in blue. 
Abbreviations: SNr (substantia nigra pars 
reticulate), SNc (substantia nigra pars 
compacta), GPe (external globus pallidus), GPi 





microscopy suggested complete segregation of neurons expressing D1R and D2R77,78, but 
other studies using fluorescence imaging provided evidence both for48,79 and against78 
receptor co-localization in about 20% of striatal neurons. EGFP expression driven by 
either D1R or D2R gene promoters in BAC mice indicated complete cellular segregation 
of receptor expression80. In situ detection of D1R and D2R mRNA showed conflicting 
evidence76,81–83, while reverse transcriptase PCR of single striatal neurons detected co-
expression in about 17% of MSNs84,85. Additionally, the few MSNs that co-expressed 
enkephalin with dynorphin29, or enkephalin with substance P85, also co-expressed D1R 
and D2R. Interestingly, neurons co-expressing D1R and D2R may exhibit processes that 
exclusively express only D1R or only D2R receptors48. These findings, along with the 
methods of detection and visualization may be the reason for incongruent reports over 
D1R and D2R neuronal co-localization.  
It was originally thought that the D1R and D2R were functionally opposed, based 
on their known regulation of adenylate cyclase (Figure 4, Figure 5)86,87. However, in the 
late 1980s, behavioral studies found that co-administration of D1R and D2R agonists 
elicited behaviors not seen when administered separately. These behaviors could be 
reduced with the addition of either a selective D1R or D2R antagonist, demonstrating the 
need for stimulation of both receptors at the same time. Electrophysiological studies 
presented similar results with simultaneous D1R and D2R stimulation in various regions 
of the brain such as the substantia nigra and nucleus accumbens88. Additional studies 
found evidence for D1R and D2R synergism in striatal neurons resulting in altered 
animal behavior89–92. While it was likely that behavioral changes induced by D1R and 
D2R ligands were due to integration of D1R and D2R signaling at the circuit level, the 
13 
 
question remained whether at least part of the behavioral changes could be attributed to 
D1R-D2R synergism at the cellular level. 
In the 1990s, “D1-like” receptor stimulation was suggested to involve 
intracellular Ca2+ mobilization as a result of Gq-mediated activation of phospholipase C 
in striatal neurons93–96. This suggested that an alternate mechanism for D1R-related 
signaling existed. In 2004, Susan George and colleagues published data suggesting the 
existence of a D1R-D2R heteromer linked to stimulation of intracellular Ca2+ 
mobilization48. By heterologously co-expressing D1R and D2R in HEK293T and COS7 
cells, they were able to observe an intracellular Ca2+ response after treatment with DA or 
co-treatment with selective D1R and D2R agonists. Ca2+ mobilization was not seen in 
cells transfected with only the D1R or D2R, with treatment with selective D1R or D2R 
agonists alone, or when the D1R-D2R co-transfected cells were stimulated with DA and 
incubated with either a D1R or D2R selective antagonist. This indicated that the Ca2+ 
response requires co-expression and co-activation of both D1R and D2R48.  
Additional publications from the George lab suggested the existence of D1R-D2R 
heteromers in the striatum, especially in the ventral striatum of human and rat brain. 
Importantly, studies using confocal FRET techniques argued for direct demonstration of 
the existence of D1R-D2R heteromers in 10-20% of the cell bodies and pre-synaptic 
terminals of MSNs within the nucleus accumbens29,97–99, and the two DARs have been 
shown to co-internalize following selective activation of either receptor100,101. Moreover, 
they showed that the D1R-D2R heteromer stimulated Gq protein-mediated intracellular 
Ca2+ release48,102, and they were able to see co-internalization of the two receptors 
following co-stimulation of the heteromer100,101.  
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The George lab then identified and studied several structurally similar compounds 
from the benzazepine family that were able to selectively activate the D1R homomer (as 
defined by adenylate cyclase activation) or the D1R-D2R heteromer103. One such 
compound, SKF83822, only activates the D1R homomer, while another compound, 
SKF83959, was suggested to selectively activate the D1R-D2R heteromer102 (Figure 7).  
 
Interestingly, other labs had already observed the unusual pharmacology of 
SKF83959. Undie et al. found that SKF83959 antagonized D1R-coupled cAMP 
formation and, instead, induced striatal intracellular Ca2+ mobilization in rats and 
monkeys104. SKF83959 did not cause epileptic seizures in rodents105, unlike D1R 
agonists that stimulate cAMP production. Paradoxically, SKF83959 seemed to cause 
typical D1R agonist-like behaviors in rats29, and is an effective anti-parkinsonian agent in 
MPTP-lesioned monkeys that are unresponsive to L-DOPA106. SKF83959’s seemingly 
conflicting pharmacological actions have been proposed to be due to its unique D1R-D2R 
 
Figure 7: Differential effects of structurally similar benzazepines, SKF83959 and SKF83822, on 
DAR signal transduction.  
A: SKF83822 acts as a D1R homomer agonist which activates stimulatory Gs/olf proteins, causing 
cAMP formation. B: Benzazepines do not target homomeric D2Rs, which couple to inhibitory Gi/o 
proteins, inhibiting cAMP formation. C: SKF83959 was suggested to activate the D1R-D2R heteromer 
to induce a phospholipase C β-induced Ca2+ response (Rashid et al., 2007). See Figure 4 and Figure 5 





heteromer-specific targeting, which might also account for its ability to treat L-DOPA-
resistant parkinsonian monkeys with very little of the side effects that are typical of drugs 
used to treat Parkinson’s disease30. These findings also presented tantalizing evidence 
that D1R-D2R heteromer specific drugs could be used to effectively treat neurological 
diseases without inducing the severe side effects seen with most drugs. 
 It is clear from these previous studies that the D1R and D2R can function 
synergistically to induce Ca2+ mobilization. However, these studies did not conclusively 
address whether the receptors function as a part of a dimer or a larger heteromeric 
complex. Also, all functional studies investigating D1R-D2R interactions in transfected 
cells used D2LR instead of D2SR, raising the issue that the observed phenomena might 
be isoform specific. Importantly, there is evidence that the 3rd intracellular loop (ICL), 
which is the only region of difference between D2LR and D2SR, can affect the G protein 
coupling and signaling capabilities for each D2R isoform107. Pei et al. found that a protein 
fragment unique to the 3rd ICL of the D2LR, which is absent in the D2SR, could 
associate with the D1R using a “pull down” assay31. The same fragment could also block 
co-immunoprecipitation of the D1R and D2R, consistent with the hypothesis that the 3rd 
ICL is an important region for D1R-D2R heteromer formation31. Pei et al. did not test the 
ability of other D2R regions to affect heteromer formation, nor did they do a co-
immunoprecipitation of the D1R and D2SR, but their results do provide some evidence 
for isoform-dependent heteromerization of the D1R and D2R. 
Many other GPCRs have been found to form homo- or hetero-oligomers with 
biochemical and functional characteristics that are unique to their oligomeric 
conformations108–110. These GPCR oligomers have been found to occur across different 
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classes, families, types, and subtypes111. Additionally, the internalization and degradation 
of GPCRs in homo- and hetero-oligomers has been found to differ from their homomeric 
counterparts108,111–115. The interaction between GPCR oligomers and their targets can be 
asymmetrical or symmetrical and, most intriguingly, a homo- or heteromer specific 
ligand can be functionally selective. Functional selectivity, also termed biased agonism, 
is a relatively new pharmacological concept. A ligand is functionally selective if it 
stimulates or inhibits one specific signaling pathway of a receptor that has many possible 
signaling pathways (see Chapter 3 Introduction). 
 GPCRs may exist in various constantly changing structural conformations, and a 
functionally selective ligand may bias the GPCR towards a specific conformation that 
limits its spectrum of signaling capabilities116. The evidence for a D1R-D2R heteromer 
selective ligand (SKF83959) along with the unknown structural and pharmacological 
properties of the heteromer is compelling. The discovery of novel small molecule ligands 
specifically targeting the D1R-D2R heteromer could aid, not only in drug discovery and 
development, but also in the characterization of the heteromer itself. This idea does not 
come without precedent, as other homo- and heteromeric GPCRs have been found to 
have oligomer-specific ligands with unique downstream coupling and signaling 
properties. For instance, a δ-opioid receptor antagonist, naltriben mesylate, exhibited 
biased antagonism when it was found to block internalization of heteromers composed of 
δ-opioid and μ-opioid receptors without inhibiting heteromer-mediated G protein 
activation117. Likewise, a κ-opioid receptor agonist, 6’-GNTI, was found to activate the 
κ-opioid receptor only when in a complex with the μ-opioid receptor118. 
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While the precise mechanism for this type of signaling and its prevalence in vivo 
remains unclear, heteromer selective compounds could aid in furthering our 
understanding of heteromer structure, pharmacology and function in vivo. It has been 
reported that D1R-D2R co-activation results in increased Ca2+/calmodulin-dependent 
protein kinase II α (CaMKIIα) levels in the striatum, resulting in enhanced brain-derived 
neurotrophic factor (BDNF) expression and increased neuronal maturation and 
differentiation97,102,119. BDNF is a growth factor that affects differentiation, growth, and 
survival of neurons and activation of the heteromer may have profound effects on 
neuronal plasticity. It was also shown that, when injected into rats, expression of 
glutamate decarboxylase-67 and the vesicular glutamate transporters 1 and 2 in striatal 
neurons was altered by SKF83959120, which was interpreted to be due to selective D1R-
D2R heteromer activation.  
In the current study, we further investigate the biology and pharmacology of the 
proposed D1R-D2R heteromer and the mechanism of Ca2+ mobilization in heterologous 
expression systems. While we find that co-activation of both D1Rs and D2Rs are 
required for Ca2+ mobilization to occur, there appear to be multiple mechanisms through 
which this pathway is elicited. We also studied the pharmacological characteristics of 
SKF83959, to determine its putative activity as a heteromer selective ligand, and found 
that it was significantly less selective than previously proposed. In fact, we were not able 
to provide evidence for activation of the D1R-D2R heteromer by SKF83959. These 
results indicate that D1Rs and D2Rs can synergize to induce Ca2+ mobilization, although 




Materials and Methods 
Materials – HEK293-tsa201 (HEK293T) cells were a gift from Dr. Vanitha 
Ramakrishnan. A D1R expressing stable cell line was purchased from Codex 
Biosolutions, Inc. (Gaithersburg, MD). [3H]-SCH23390 (80.5 Ci/mmol) and [3H]-methyl-
spiperone (85.5 Ci/mmol) was obtained from PerkinElmer Life Sciences (Waltham, MA). 
Cell culture media and reagents were purchased from MediaTech/Cellgro (Manassas, 
VA). Cell culture flasks and materials and all assay plates were purchased from Greiner 
Bio-One (Monroe, NC). SKF83959 and SKF83822 were purchased from Tocris 
Bioscience/RD Systems (Minneapolis, MN). All other compounds and buffer 
components were purchased from Sigma-Aldrich (St Louis, MO), except where 
indicated. 
 
Cell Culture and Transfection – HEK293T cells and D1R CODEX cells were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with a final 
concentration of 10% fetal bovine serum, 100 units/ml penicillin, 100 μg/ml 
streptomycin, 1 mM sodium pyruvate, and 10 μg/ml gentamicin. Cells were incubated at 
37°C, 5% CO2, and 90% humidity. They were passaged and plated mechanically using 
Ca2+-free Earle’s balanced salt solution (EBSS) and pelleted by centrifugation at 1000 
rpm for 10 min. For transfection studies, HEK293T cells were seeded in 150 mm plates 
at 10 × 106 cells per plate. After 24 h, cells were transfected according to the 
manufacturer’s recommendations using Clontech’s CalPhosTM transfection kit (Clontech 
Laboratories, Inc., Mountain View, CA). The DAR plasmid constructs were FLAG-
tagged rat D1R, D2SR, or D2LR in the pCD-SRα vector121–123 and D4R in pcDNA3.1(+) 
vector124. Additional experiments were done using the Gq protein in the pcDNA3.1(+) 
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vector (Missouri S&T cDNA Resource Center, Rolla, MO) and various functionally 
dominant negative GRK2 mutants: GRK2 C-terminus 495-689 in pcDNA3(+), GRK2 
K220R in pcDNA3(+), and empty pcDNA3.1(+)125,126. For all transfections, 5 μg of each 
DNA construct was used to transfect cells, with the exception of D1R, in which 10 μg 
was used.  
 
Radioligand Binding Assays – 48 h after transfection, cells were dissociated from plates 
using Ca2+-free Earle’s balanced salt solution (EBSS), and intact cells were collected by 
centrifugation at 900  g for 10 min. Cells were resuspended and lysed using 5 mM Tris-
HCl and 5 mM MgCl2 at pH 7.4 at 4°C. Cell lysate was pelleted by centrifugation at 
20,000 × g for 30 min and resuspended in 5 mM Tris-HCl at pH 7.4. 100 μL cell lysate 
(containing 8 g protein for D2R assays or 10 g protein for D1R assays) was incubated 
for 90 min at room temperature with various concentrations of [3H]-SCH23390 (D1R 
binding) or [3H]-methyl-spiperone (D2R binding) in a final reaction volume of 250 μl. 
Non-specific binding was determined in the presence of 4 μM (+)-butaclamol. Bound 
ligand was separated from the unbound by filtration through a PerkinElmer Unifilter-96 
GF/C 96 well micro-plate using the PerkinElmer Unifilter-96 Harvester, washing 3 times, 
1 ml per well in ice-cold assay buffer. After drying, 50 μl of liquid scintillation cocktail 
(MicroScint PS, Perkin Elmer, Waltham, MA) was added to each well, plates were 
sealed, and analyzed on a PerkinElmer Topcount NXTTM. For competition binding 
assays, a fixed concentration of 0.5 nM [3H]-SCH23390 was incubated with various 
concentrations of SKF83959, and the remainder of the assay was performed as described 
above. Ki values were calculated from observed IC50 values using the Cheng-Prusoff 
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equation and a Kd value of 0.5 nM for SCH23390, as determined in independent 
saturation isotherms (data not shown). Expression of the D4R was determined in an 
identical assay format as that for the D2R.  
 
Competition Radioligand Binding Screen – A primary, single-point, radioligand 
competition binding assay was performed to assay for radioligand binding inhibition by 
SKF83959 (10 μM). Forty-three GPCRs and other drug targets were screened in the 
primary assay using radioligands with known binding properties. Percent inhibition was 
calculated by subtracting percent specific binding in the presence of the test compound 
from the percent specific binding in the absence of the test compound, (N=4). Receptors 
whose corresponding radioligands had greater than 50% inhibition at 10 μM SKF83959 
underwent secondary radioligand competition binding assays to generate full competition 
curves. Ki determinations and receptor binding profiles were provided by the National 
Institute of Mental Health (NIMH) Psychoactive Drug Screening Program (PDSP), 
Contract # HHSN-271-2008-00025-C. The NIMH PDSP is directed by Dr. Bryan L. Roth 
(University of North Carolina, Chapel Hill, NC) and by Project Officer Jamie Driscol 
(NIMH, Bethesda, MD). For experimental details including radioligands used and 
associated Kd values for each individual receptor, please refer to the PDSP website 
http://pdsp.med.unc.edu/. 
 
Ca2+ Mobilization Assays – Assays were performed as previously described. HEK293T 
cells were transiently transfected as described. 24 h after transfection, cells were plated in 
384-well, optical, clear bottom, black walled plates (20 μL/well, 30,000 cells/well; 
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Greiner Bio-one, Monroe, NC). 48 h following transfection, cells were incubated for 60 
min at room temperature in the dark with Fluo-8 NW Ca2+ dye and an extracellular signal 
quencher to block any signal from extracellular Ca2+ (Screen Quest™ Fluo-8 NW 
Calcium Assay Kit, AAT Bioquest, Inc., Sunnyvale, CA), as recommended by the 
manufacturer. The plates were then treated with various concentrations of antagonist or 
agonists (diluted in the presence of 0.2 mM sodium metabisulfite) as indicated in the 
results and figure legends. For agonist reads, plates were read in real time kinetically 
(every 0.6 sec) by recording a baseline read for 14 sec prior to addition of an agonist 
compound and then continually measured for 2 min after agonist addition. For antagonist 
reads, plates were read in real time kinetically (every 0.6 sec) by recording a baseline 
reading for 20 sec prior to addition of that antagonist. Then, three min later, agonist 
compound was added and the plates were read for an additional 3 min. All compound 
additions were done in unison using the 384-tip onboard robotics on an FDSS μCell 
(Hamamatsu, Bridgewater, NJ), and plates were continuously read using the FDSS μCell 
from the bottom throughout the assay with an excitation wavelength of 480 nm and an 
emission wavelength of 540 nm. Data were recorded and quantified as maximum minus 
minimum (max-min) RFU within the assay window using FDSS software. Data are 
expressed as a percentage of the control max-min RFU for given studies as indicated in 
the figure legends. In these experiments, D1R and D2R receptor expression levels 
typically varied between 1-3 pmol/mg protein. We found that co-expressing both 
receptors sometimes affected their expression compared to expressing them alone (data 
not shown). However, this did not affect the Ca2+ mobilization response, which, while not 




Statistical analysis – Data are expressed as a percentage of control values for individual 
experiments. Non-linear regression of all data was conducted on GraphPad Prizm 5.01 
(GraphPad Software, Inc., La Jolla, CA). Results are expressed as mean ± S.E.M. 
Cell Culture and Transfection—HEK293T cells were cultured in Dulbecco’s modified 
essential medium (DMEM) supplemented with 10% fetal bovine serum, 1 mM sodium 
pyruvate, 50 units/ml penicillin, 50 μg/ml streptomycin, and 10 μg/ml gentamycin. Cells 
were grown at 37°C in 5% CO2 and 90% humidity. Untagged rat D1R
122 in pcDNA3 and 
FLAG-tagged rat D2LR127 were expressed singly or dually in HEK293T cells. Tag2B in 
pCMV (Stratagene, La Jolla, CA) was used as a negative control for FLAG-tagged 
D2LR. HEK293T cells were transfected using the calcium phosphate precipitation 
method for each experiment as follows: 5 million cells were seeded in 150 mm culture 
dishes, then transfected 24 h later with 15 μg of DNA of expression construct. After 24 h, 
the media was exchanged and experiments performed the following day. 
 
Immunoprecipitation and Gel Electrophoresis – Cells were removed from culture dishes 
and collected by centrifugation (300 × g). They were then resuspended in 1 ml of 
solubilization buffer (50 mM HEPES, 1 mM EDTA, 10% glycerol, 1% Triton X-100, 
150 mM NaCl, 50 mM NaF, 40 mM sodium pyrophosphate, and Complete-Mini; Roche 
Applied Science, Indianapolis, IN) protease inhibitor mixture and incubated on an orbital 
shaker at 4°C for 1 h. The lysates were transferred to 1.5 ml Axygen tubes and 
microfuged at 26,000 × g for 40 min. The lysates were pre-cleared using Protein G-
agarose beads on an orbital shaker at 4°C for 3 h then microfuged for 5 min at 1000 × g. 
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Lysates transfected with FLAG-D2LR were transferred to 100 μl of anti-FLAG M2-
agarose beads (Sigma-Aldrich, St. Louis, MO) equilibrated in solubilization buffer and 
rotated on an orbital shaker at 4°C overnight. Lysates of non-transfected cells or cells 
transfected with non-tagged D1R were removed from the Protein G-agarose pellets and 
stored at 4°C overnight. The anti-FLAG M2-agarose beads were collected via 
centrifugation and washed three times by resuspension and recentrifugation in 
solubilization buffer. The agarose was then subjected to a final wash in 1× TE buffer, pH 
7.4 plus protease inhibitors. Proteins were eluted from the beads using 70 μl of NuPAGE-
lithium dodecyl sulfate sample buffer (Invitrogen, Carlsbad, CA) at 37°C for 1 h, then 
microfuged at 2500 × g for 2 min to remove agarose beads and 30 μl of each supernatant 
was loaded on duplicate gels. 20 μl of lysate from non-transfected cells or cells 
transfected with untagged D1R was mixed with 40 μl of LDS buffer, mixed, then divided 
in half and loaded in duplicate gels. Proteins were resolved on duplicate 4–12% BisTris 
NuPAGE gels in MOPS buffer (Invitrogen, Carlsbad, CA) for 1 h at 195 V, constant 
voltage.  
 
Western Blotting and Chemiluminescent Development – Proteins separated by PAGE 
were transferred onto polyvinylidene difluoride membranes for 1 h at 30 V constant 
voltage. Membranes were blocked in blocking solution (1% BSA, 0.01% Tween 20 in 
TBS) for 1 h at room temperature prior to incubation with the primary antibody. Primary 
antibodies used in this study include the following: rat monoclonal anti-D1R (clone 1-1-
F11 S.E6, catalog number D-187, Sigma-Aldrich, St. Louis, MO) and rabbit polyclonal 
anti-D2L/SR (catalog number AB5084P, Chemicon, Temecula, CA). Primary antibody 
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solutions were diluted 1:10,000 for D1R primary and 1:1000 for D2L/SR primary in 
blocking solution. Each PVDF membrane was exposed to a single primary antibody 
solution (D1R or D2LR) overnight at 4°C on orbital shaker. Primary antibody solutions 
were removed and each membrane was washed three times, 5 min each in TBST. 
1:10,000 dilutions in blocking solution were prepared for each HRP-conjugated 
secondary antibody (Jackson ImmunoResearch, West Grove, PA; anti-rat for the D1R 
and anti-rabbit for the D2LR). Membranes were incubated in appropriate secondary 
antibody solution for 1 h at room temperature on an orbital shaker. Membranes were 
washed three times, 5 min each in TBST. Proteins were visualized via the SuperSignal 
West Pico Chemiluminescent Substrate Kit or the SuperSignal West Dura 
Chemiluminescent Substrate (Pierce, Rockford, IL) according to the manufacturer's 




Previous studies have suggested that the D1R-D2R receptor complex may signal 
as a heteromer and have implicated SKF83959 as a compound that may selectively 
activate this signaling complex48,100,102,103. However, these findings have not been 
corroborated and the mechanisms by which the D1R-D2R receptor complex signals 
remain unclear. To investigate the apparent ability of D1R-D2R receptor oligomerization 
to alter the G protein coupling of component receptors, we first transiently expressed the 
D1R either alone or concurrently with either the short (D2S) or long (D2L) isoforms of 
the D2R and measured intracellular Ca2+ mobilization via kinetic fluorescence imaging. 
Preliminary co-immunoprecipitation experiments revealed that D1R-D2R hetero-
oligomers were indeed capable of forming under these expression conditions (Figure 8).  
 
 
Figure 8: Co-immunoprecipitation of the D1R and D2LR.  
Small arrows indicate the location of the D2LR in lane 7 and the D1R in lanes 3 and 5. The filled arrow 
indicates a non-specific background band as it is observed in non-transfected cells. HEK293T cells 
were transfected with either the FLAG-tagged D2LR, the non-tagged D1R, the D1R with a vector that 
expressed only the FLAG peptide (Tag2B), or the D1R with the FLAG-tagged D2LR, as indicated on 
the blots. Proteins were extracted and lysates were either electrophoresed or immunoprecipitated (IP) 
using anti-FLAG agarose beads, and immunoblotted (IB). IBs were probed using either a D2L/SR 
primary antibody or a D1R primary antibody. Lanes 1, 3, and 6 were loaded with whole cell lysate, 
while the remaining lanes underwent IP prior to being loaded on the gel. In this experiment, the D2R is 
IPed using an anti-FLAG antibody and appears in lane 7 as multiple glycosylated protein bands. The 
D1R appears as a single glycosylated protein band of ~60 kDa that is co-IPed with the D2R, as shown 
in lane 5. In contrast, the D1R does not co-IP with a peptide containing just the FLAG sequence 
(Tag2B), as shown in lane 4. 
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When cells were transfected with the D1R and D2LR or the D1R with D2SR, a 
clear dose-dependent activation of Ca2+ mobilization was observed in response to DA 
(Figure 9). Importantly, we observed no difference in coupling efficacy or agonist 
potency between the short and long isoforms of the D2R. However, when cells were 
transfected with any of the subtypes alone, the receptors failed to couple to Ca2+ 
mobilization (Figure 9). These data suggest that expression and activation of both the 
D1R and D2R are essential for coupling to Ca2+ mobilization and signaling.  
 
To further investigate that the activation of both receptor subtypes is required to 
stimulate Ca2+ mobilization, we utilized receptor subtype selective antagonists. 
Concentration response inhibition curves for the D1R- selective (SCH23390) and the 
D2R selective (sulpiride) antagonists were generated for cells transfected with the D1R 
and D2R (Figure 10). Cells were simultaneously stimulated with 1 μM DA and examined 
for Ca2+ mobilization. We observed complete inhibition of the Ca2+ signal with either 
SCH23390 or sulpiride treatment. The potencies of the antagonists (SCH23390 IC50 ~8.0 
 
Figure 9: Agonist-induced Ca2+ mobilization in DA receptor transfected cells.  
HEK293T cells were transiently transfected with D1R, D2LR, D2SR, D1R+D2LR, or D1R+D2SR as 
indicated and described in the methods. 24 h later, cells were plated in 384-well plates and assayed the 
following day for Ca2+ mobilization following stimulation by DA (D1R+D2LR EC50=73.8 nM, 
D1R+D2SR EC50=58.2 nM). Data are representative of three independent experiments done with the 
same assay conditions on different days. Data are expressed as percentage of control, normalized to the 
maximum signal seen via DA stimulation of D1R+D2LR transfected cells. Error bars indicate S.E.M. 




nM, sulpiride IC50 ~0.7 nM) are consistent with their known affinities for their selective 
subtypes as determined in the Sibley laboratory (data not shown) as well as other 
groups128,129. More importantly, complete inhibition of the Ca2+ response is seen at 
antagonist concentrations that have no effect on the opposite receptor subtype. Thus, 
selectively blocking DA activation of either receptor subtype is sufficient to prevent Ca2+ 
mobilization further suggesting that both receptor protomers must be activated for this 
signaling to occur.  
 
While the studies employing subtype selective antagonists suggested that both 
D1R and D2R are required for Ca2+ signaling, it might be possible that stabilizing one 
subtype into an inactive state within a heteromer might alter the conformation of the 
corresponding partner. Thus, to further elucidate the coupling mechanism, subtype 
selective agonists were used to determine if indeed activation of both protomers are 
required for Ca2+ mobilization. As seen in Figure 11, concurrent administration of a D1R 
selective (SKF83822) and a D2R selective (quinpirole) agonist to cells co-transfected 
 
Figure 10: Inhibition of D1R+D2LR-mediated Ca2+ mobilization by either D1R- or D2R selective 
antagonists.  
HEK293T cells were transfected with D1R+D2LR as described and 24 h later were plated in 384-well 
plates. Cells were incubated with the indicated concentrations of the D1R selective antagonist 
SCH23390 (A) or the D2R selective antagonist sulpiride (B), and then stimulated with an EC80 of DA 
(1 μM; SCH23390 IC50=8.0 nM, sulpiride IC50=0.7 nM). Data are expressed as a percentage of the 
control (10 μM) DA response and are representative of two independent experiments performed with 




with D1R and D2R resulted in a Ca2+ mobilization response that nearly matched that of 
DA. In contrast, when D1R plus D2R co-transfected cells were stimulated with 
quinpirole alone, no Ca2+ mobilization was observed. Furthermore, when the co-
transfected cells were stimulated with SKF83822, no Ca2+ mobilization was seen at 
concentrations selective for D1R. A small response was observed at 10 μM, but this was 
at a concentration where SKF83822 loses receptor subtype selectivity and can begin to 
stimulate the D2R as well. Previous studies showed that SKF83822 has an affinity for 
D1R in the ~2 nM range and D2R in the ~200 nM range130. Experiments done in our lab 
have demonstrated a D2R affinity that is greater than 10 μM (data not shown), supporting 
the idea that the SKF83822-mediated Ca2+ response seen at high concentrations is due to 
non-selective receptor activation. In addition, when cells were transfected with any of the 
subtypes individually, no signal was seen from any of the agonists (data not shown). 
Taken together, these data indicate that stimulation of both receptor subtypes is necessary 
for Ca2+ mobilization.  
 
 
Figure 11: Stimulation of D1R+D2LR-mediated Ca2+ mobilization by either D1R- or D2R 
selective agonists. 
HEK293T cells were transfected with D1R+D2LR as described, plated 24 h later in 384-well plates, 
and assayed for Ca2+ accumulation the following day. Cells were stimulated with one of the following 
agonists as indicated: DA, the D1R selective agonist SKF83822, the D2R selective agonist quinpirole, 
or both SKF83822 and quinpirole (D1R+D2LR EC50=610.8 nM) combined. Control cells expressing 
the D1R, D2SR, or D2LR individually did not show a significant Ca2+ response to concurrent agonist 
administration. Data are expressed as a percentage of control maximum DA stimulated response and are 
representative of two independent experiments performed with the same assay conditions on different 





Previous studies suggested that SKF83959 may be a D1R-D2R heteromer 
selective compound and a significant Ca2+ response to this ligand has been reported in 
cells co-expressing the D1R and D2R27,48,102,103. This compound has also been reported to 
have seemingly paradoxical effects on the D1R, exhibiting both antagonist and agonist 
properties depending on the system30,104,131. In our current studies, we treated D1R and 
D2R co-transfected cells with SKF83959 and, surprisingly, were unable to elicit a Ca2+ 
response (Figure 12A). Furthermore, when SKF83959 was added in concert with the 
D2R selective agonist quinpirole, we were still unable to observe a significant Ca2+ 
response. It should be noted that SKF83959 consistently failed to stimulate Ca2+ 
mobilization even when this experiment was performed using different lots of compound 
from different vendors on separate days, as well as with different drug solvents (data not 
shown). We also had one lot of compound chemically analyzed to verify its purity (data 
not shown).  
To demonstrate that the SKF83959 compound was pharmacologically active in 
our hands, we performed two separate experiments. In Figure 12B, we stimulated Ca2+ 
mobilization with DA and then dose-dependently added either the D1R selective 
antagonist SCH23390 as a control (see Figure 10A) or SKF83959 to see if it might 
function as an antagonist in this system. In fact it did, exhibiting even higher potency 
than SCH23390, although its efficacy of antagonism was less, exhibiting a maximum 
inhibition of ~50%.  
Finally, we performed a radioligand binding competition assay with SKF83959 
and cells transfected with the D1R (Figure 12C). SKF83959 was able to potently and 
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fully compete for radioligand binding to the D1R. These experiments (Figure 12B, C) 
demonstrate that SKF83959 is active in binding to the homomeric D1R as well as active 
as a partial antagonist of the Ca2+ response observed in D1R and D2R co-transfected 
cells. In contrast, it does not appear to function as an agonist with respect to stimulating 




Figure 12: Pharmacological characterization of SKF83959 on D1R+D2LR-mediated Ca2+ 
mobilization.  
HEK293T cells were transfected with D1R+D2LR as described, plated 24 h later in 384-well plates, 
and assayed for Ca2+ accumulation the following day. A: Cells were stimulated with one of the 
following conditions as indicated: DA, SKF83959, the D2R selective agonist quinpirole, or both 
SKF83959 and quinpirole combined. B: Cells were incubated with SKF83959 or the D1R selective 
antagonist SCH23390, then stimulated with an EC80 of DA (1 μM). Data are expressed as a percentage 
of control maximum DA-stimulated response and are representative of 2-3 independent experiments 
performed with the same assay conditions on different days. Error bars indicate S.E.M. from multiple 
wells within the representative experiment. C: HEK293 cells stably transfected with D1R (Codex 
Biosolutions, Inc., Gaithersburg, MD) were grown and membranes harvested according to the materials 
and methods. Membranes were incubated with various concentrations of SKF83959 and 0.5 nM [3H]-
SCH23390 as indicated. Graph is representative of two independent experiments done on different 
days. Data are expressed as specific binding in units of fmol/mg. Ki value was calculated using the 
Cheng-Prushoff equation and a radioligand Kd value of 0.5 nM as determined via saturation binding 
isotherms (data not shown). Average Ki for SKF83959 on D1R was 2.6 nM ± 0.7. 
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Given the apparent discrepancies of our findings with some previous 
studies48,103,132, and the possibility that SKF83959 may not be as selective as previously 
thought, we sought to screen its selectivity against various GPCRs. This was 
accomplished through collaboration with the NIMH Psychoactive Drug-Screening 
Program (http://pdsp.med.unc.edu). For the primary screen, a single-point radioligand 
binding competition experiment was performed with 10 μM SKF83959 as a competitor 
against an appropriate receptor-specific radioligand of known properties. Forty-three 
GPCRs and signaling proteins were screened this way and twenty of them exhibited 
>50% inhibition at 10 M SKF83959 (Table 1). In contrast, twenty-three GPCR targets 
were found to have <50% inhibition at 10 M SKF83959 and were therefore considered 
relatively “inactive/low affinity” for SKF83959 (Table 2).  
The twenty “active” receptors/proteins underwent secondary radioligand 
competition binding experiments to generate full competition curves for SKF83959 and 
Ki values for these receptors were determined and shown in Table 1. Of note is that the 
serotonin 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A and 5-HT6 receptors, the adrenergic α2A, 
α2B and α2C receptors, the D1, D2, and D5 receptors, and the serotonin transporter all 
have sub-micromolar Ki values. SKF83959 demonstrated very high (<100 nM) affinity 
for four of these GPCRs: the serotonergic receptor subtypes 5-HT2C, the adrenergic 
receptor subtype α2C, the D1, and D5 receptor subtypes, and the serotonin transporter. 
Notably, SKF83959 has also recently been shown to be a potent allosteric modulator of 
the sigma-1 receptor133. Taken together, these data indicate that SKF83959 has 
significantly high affinity for a wide number of receptors and thus caution should be 









5-HT1A 1648.0 352.3 
5-HT2A 246.6 32.1 
5-HT2B 405.0 145.1 
5-HT2C 32.8 13.3 
5-HT5A 277.8 141.8 
5-HT6 546.0 56.0 
α1A 1290.5 154.5 
α1D 1115.5 232.4 
α2A 323.7 120.6 
α2B 163.1 17.8 
α2C 31.1 7.6 
D1R 1.7 0.8 
D2R 567.0 150.0 
D3R 1018.3 109.8 
D4R 1975.7 756.4 
D5R 4.0 0.1 
H2 1699.3 640.3 
M4 5238.5 1985.5 
M5 3484.0 114.0 
SERT 365.6 79.2 
 
Ki values were derived from radioligand binding competition curves generated against each of the 
above targets (n=2) as described in the Materials and Methods section. Abbreviations: 5-HT1A 
(serotonergic receptor subtype 1A), 5-HT2A (serotonergic receptor subtype 2), 5-HT2B (serotonergic 
receptor subtype 2B), 5-HT2C (serotonergic receptor subtype 2C), 5-HT5A (serotonergic receptor 
subtype 5A), 5-HT6 (serotonergic receptor subtype 6), α1A (α-adrenergic receptor subtype 1A), α1D 
(α-adrenergic receptor subtype 1D), α2A (α-adrenergic receptor subtype 2A), α2B (α-adrenergic 
receptor subtype 2B), α2C (α-adrenergic receptor subtype 2C), M4 (muscarinic receptor subtype 4), M5 
(muscarinic receptor subtype 5), SERT (serotonin transporter). 
Table 2: List of various GPCR targets with low / no affinity for SKF93959. 
5-HT1B β2 H1 M3 
5-HT1D β3 H3 MOR 
5-HT1E BZP Rat brain H4 NET 
5-HT3 DAT KOR σ1 
α1B DOR M1 σ2 
β1 GABAA M2  
Receptors showed less than 50% inhibition of binding by 10 μM SKF83959, and therefore were 
classified as having low to no affinity for the compound. The percent inhibition was calculated by 
subtracting % radioactivity bound to filter from 100% radioligand (n=4). The NIMH Psychoactive Drug 
Screening Program, as referenced in Table 1, generously provided the binding profiles. Abbreviations: 
5-HT1B (serotonergic receptor subtype 1B), 5-HT1D (serotonergic receptor subtype 1D), 5-HT1E 
(serotonergic receptor subtype 1E), 5-HT3 (serotonergic receptor subtype 3), 1B (-adrenergic 
receptor subtype 1B), β1 (β-adrenergic receptor subtype 1), β2 (β-adrenergic receptor subtype 2), β3 (β-
adrenergic receptor subtype 3), BZP Rat Brain Site (allosteric benzodiazepine binding site on GABAA 
receptor), DAT (dopamine transporter), DOR (δ-opioid receptor), GABAA (ionotropic GABA 
receptor), H1 (histamine receptor subtype 1), H3 (histamine receptor subtype 3), H4 (histamine receptor 
subtype 4), KOR (κ-opioid receptor), M1 (muscarinic receptor subtype 1), M2 (muscarinic receptor 
subtype 2), M3 (muscarinic receptor subtype 3), MOR (μ-opioid receptor), NET (norepinephrine 




While D1 and D2 receptors appear capable of signaling through Ca2+ mobilization 
when both receptors are stimulated, the mechanism of transduction remains unclear. To 
better understand the mechanisms involved, we tested the hypothesis that the receptors, 
perhaps within the context of a heteromer, may switch G protein-coupling selectivity and 
gain the ability to activate Gq. We first examined this possibility by over-expressing Gαq 
in cells expressing the D1R+D2R. Interestingly, the resulting DA-stimulated Ca2+ signal 
was increased by 200% when compared to cells transfected with the D1R+D2R alone 
(Figure 13A). Expression of only the Gαq protein in the absence of either receptor did not 
enable the ability of DA to stimulate Ca2+ mobilization (Figure 13A). In parallel studies, 
we examined how over-expression of Gαq with the D1R or D2R alone could couple to 
intracellular Ca2+ mobilization. While cells transfected with D1R or D2R alone did not 
give a Ca2+ response, consistent with Figure 9, when Gαq was over-expressed, the D1R 
was able to elicit a DA-stimulated Ca2+ signal in the absence of the D2R (Figure 13B), 
although the Ca2+ response was not as large as that seen with the D1R+D2R+Gαq 
transfection (cf. Figure 13A and B). No such phenomenon was observed with the D2R. 
Taken together, these data suggest that the Gq protein may be involved in Ca
2+ 
mobilization mediated by a D1R-D2R heteromer, however, this interpretation is 





Given our results with Gαq over-expression, we re-evaluated SKF83959-
stimulation of Ca2+ mobilization under these conditions in the D1R and D2R co-
expressed cells. We found that with Gαq over-expression, SKF83959 is able to stimulate 
Ca2+ mobilization in a manner similar to that of DA (Figure 14A), whereas it is unable to 
stimulate such a response in cells lacking Gαq over-expression (Figure 12 and Figure 
14A). Interestingly, SKF83959 was also able to stimulate Ca2+ mobilization in cells 
expressing the D1R and over-expressing Gαq, but not D1R alone (Figure 14A). These 
results led us to test the antagonist sensitivity of the SKF83959 responses as shown in 
Figure 14B. We found that the D1R selective antagonist, SCH23390, could completely 
ablate SKF83959 stimulation of Ca2+ mobilization in both D1R+Gqα transfected as and 
D1R+D2R+Gαq transfected cells. However, in contrast to what we observed for DA 
stimulation of D1R+D2R co-transfected cells, the D2R selective antagonist, sulpiride, 
was unable to block SKF83959 stimulation of Ca2+ mobilization. These results suggest 
that over-expression of Gαq enables SKF83959 to stimulate homomeric D1R present in 
 
Figure 13: Influence of Gαq protein over-expression on D1R+D2LR-mediated Ca2+ mobilization.  
A: HEK293T cells were transfected with D1R+D2LR with and without Gαq, or with Gαq alone 
(D1R+D2R EC50=168.3 nM, ECmax=100%; D1R+D2R+Gq EC50=16.8 nM, ECmax=300.1%). B: 
HEK293T cells were transfected with D1R+D2LR, D1R, or D2R with and without Gαq (D1R+Gq 
EC50=10.3 nM, ECmax=152.2%). 24 h later cells were plated in 384-well plates and assayed the 
following day for Ca2+ mobilization following stimulation by the indicated concentrations of DA. Data 
are expressed as a percentage of control maximum DA stimulation for D1R+D2LR alone and are 
representative of 2-3 independent experiments performed with the same assay conditions on different 
days. Error bars indicate S.E.M. from multiple wells within the representative experiment. 
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the D1R and D2R co-transfected cells, rather than enabling it to gain function as a D1R-
D2R heteromeric selective agonist. 
 
While the extant hypothesis, which our over-expression data support, is that Gq is 
central to the stimulation of Ca2+ mobilization, the central question is if direct coupling 
with a D1R-D2R heteromer may be involved. An alternative hypothesis is that the D1R 
and D2R signal through downstream pathways that converge on the Gq protein and/or 
other components of the Ca2+ mobilization process. In order to test whether D1R-D2R 
synergistic signaling is independent of Gi or Gs protein function, we interfered with the 
activity of Gi and Gs via treatment with toxins. D1R and D2R co-transfected cells were 
incubated overnight in media containing pertussis toxin (PTX) to inhibit Gi protein 
function67 or cholera toxin (CTX) to interfere with Gs protein function
134. Cells were then 
assayed for Ca2+ mobilization in response to DA stimulation. We found that treatment 
with either CTX or PTX drastically, but not entirely, reduced the Ca2+ response (Figure 
15). These data support the involvement of D1R-Gs- and D2R-Gi-mediated mechanisms 
that majorly contribute to the Ca2+ response in the D1R and D2R co-transfected cells.  
 
Figure 14: SKF83959 stimulates D1R-dependent Ca2+ mobilization in the presence of Gαq.  
HEK293T cells were transfected with D1R or D1R+D2LR, with or without Gαq, plated 24 h later in 
384-well plates, and assayed for Ca2+ accumulation the following day. A: Cells were stimulated with 
SKF83959. The line at 100% denotes the maximal DA response of D1R+D2LR cells. B: Cells were 
incubated with the D1R selective antagonist SCH23390 (1 μM) or the D2R selective antagonist 
sulpiride (1 μM), and then stimulated with an EC80 of SKF83959 (100 nM). Error bars indicate S.E.M. 




Another possibility, however, may be that general Gi-Gq “crosstalk” is occurring 
after receptor activation, which leads to PLC activation. Multiple cases of Gi-Gq cross-
talk in other receptor systems and cell types have been documented135–138, and Gi-Gq 
cross-talk in the D1R-D2R receptor system could account for the PTX sensitivity of the 
Ca2+ signal. In this model, any Gi-linked GPCR, not just the D2R would be able to 
support a Gq-mediated Ca
2+ response. In order to test this possibility, we used the D4R, a 
Gi-linked DAR, which has not been found to form hetero-oligomers with the D1R
139. We 
co-transfected the D1R and D4R and compared the DA response to that in the D1R+D2R 
transfected cells (Figure 16). In fact, the D4R was shown not to support a Ca2+ response 
in the presence of co-expressed D1R, indicating that non-specific Gi-Gq crosstalk, at least 
as previously described135–138 does not explain the D1R-D2R heteromer-mediated Ca2+ 
response. 
 
Figure 15: G protein dependency of D1R+D2LR-mediated Ca2+ mobilization.  
HEK293T cells were transfected with D1R+D2LR. Cells were incubated overnight in 1 μg/ml pertussis 
toxin (PTX) or 1 μg/ml cholera toxin (CTX). 48 h post-transfection, cells were assayed for Ca2+ 
mobilization via stimulation with the indicated concentrations of DA (CTX ECmax=14%, 
inhibition=86% control, PTX ECmax=24%, inhibition=76% control). Data are expressed as a percentage 
of control maximum DA stimulation seen in untreated D1R+D2LR cells, and are representative of 2-3 
independent experiments performed with the same assay conditions on different days. Error bars 




The potential involvement of multiple G-proteins led us to also investigate other 
mechanisms by which D1R and D2R activation could stimulate Ca2+ mobilization. 
Notably, G subunits have been shown to increase cytoplasmic Ca2+ concentrations by 
stimulating PLC27. A recent publication found that the ghrelin receptor-D2R heteromer-
linked Ca2+ response was PTX sensitive, required PLC activity, and could be ablated by 
sequestering the G subunits140. To see if G plays a role in the D1R-D2R heteromer-
mediated Ca2+ release, we co-transfected the D1R and D2R with two different 
functionally dominant negative G protein-coupled receptor kinase 2 (GRK2) mutants. 
The mutants we used were GRK2 K220R and the GRK2 C-terminal 495-689 peptide 
fragment (GRK2 c-term), both of which are unable to phosphorylate GPCRs, but can 
bind to, and sequester G subunits125,126. We found that over-expression of GRK2 
K220R was able to completely ablate DA-stimulated Ca2+ mobilization in the D1R and 
D2R co-transfected cells (Figure 17A). Similarly, over-expression of GRK2 c-term 
drastically reduced, but did not completely ablate, the DA-stimulated Ca2+ response 
 
Figure 16: Dopamine does not elicit a Ca2+ response in cells co-expressing the D1R and D4R.  
HEK293T cells were transiently transfected with D1R+D2LR or D1R+D4R. 24 h later cells were 
plated in 384-well plates and assayed for Ca2+ mobilization through stimulation by the indicated 
concentrations of DA. Data are expressed as a percentage of control maximum DA stimulation seen in 
cells transfected with D1R+D2LR only (EC50 = 162.0 nM), and are representative of 2-3 independent 
experiments done with the same assay conditions on different days. Expression of the D4R was 
confirmed using radioligand binding assays as described in the Materials and Methods and was similar 




(Figure 15B). These data suggest that the observed Ca2+ mobilization occurring in 
response to D1R and D2R activation is largely dependent on free G subunits.  
 
 
Figure 17: GRK2 influence on DA-mediated D1R+D2LR Ca2+ mobilization. 
HEK293T cells were transiently transfected with D1R+D2LR, and either empty pcDNA vector the 
GRK2 catalytically inactive mutant (A) GRK2 K220R (D1R+D2R EC50=269.1 nM), or the (B) GRK2 
C-terminal 495-689 fragment (D1R+D2R EC50=90.4 nM, Emax=100% control; D1R+D2R+pcDNA 
EC50=188.5 nM, ECmax=106%; D1R+D2R+GRK2 c-term EC50=288.1 nM, ECmax=30% control, 70% 
inhibition), as indicated and described in the methods. 24 h later cells were plated in 384-well plates 
and assayed following day for Ca2+ mobilization following stimulation by the indicated concentrations 
of DA. Data are expressed as a percentage of control maximum DA stimulation seen in cells transfected 
with D1R+D2LR only, and are representative of 2-3 independent experiments done with the same assay 





Receptor oligomers of many different GPCR types have been proposed to form 
homo- or hetero-oligomers with biochemical and functional characteristics that are 
unique to their oligomeric conformations108. These GPCR oligomers have been found not 
only to occur within a type of GPCR, but also across different classes, families, types, 
and subtypes111. In addition to signaling, internalization and degradation of GPCRs in 
homo- and hetero-oligomers has been found to differ from their homomeric 
activities108,111,113–115. Like previously described receptor oligomers, it has been shown 
that the D1R and D2R can co-IP with each other31,48 (Figure 8), and fluorescence imaging 
has shown that the two receptors co-internalize when one or the other receptor is 
stimulated100,101,141–143. We have demonstrated that the Ca2+ response is unique to cells 
that co-express both D1 and D2 DARs and that the DARs must be co-stimulated, as an 
antagonist to either receptor blocks the transduction. However, the mechanism of action 
and whether heteromers versus homomers form the functional units for Ca2+signaling 
remains unclear.  
It has been suggested that the co-activation of the D1R-D2R complex causes a 
conformational change that results in the direct interaction between the C-terminus of the 
D1R and the third intracellular loop (ICL3) of the D2R141. The ICL3 is the only region of 
difference between D2LR and D2SR, and there is evidence that it results in differences in 
the G protein coupling and signaling capabilities of each D2R isoform107. Recently, it 
was proposed that the ICL3 of D2LR, but not the D2SR, could form a complex with the 
D1R31, but the findings were based on the use of GST and TAT-fused D2R ICL3 
fragments, which may not accurately mimic native receptor conformations and 
interactions. Later, it was shown that both D2R splice isoforms were able to co-
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internalize with the D1R141. Our results show that both D2SR and D2LR can couple with 
the D1R to mobilize Ca2+ (Figure 9), and we have found that this is also true for both 
human (data not shown) and rat DARs. We have also confirmed that both receptors must 
be expressed in the same cell and co-activated to induce a Ca2+ response in HEK293T 
cells.  
Our data also suggest that Gq protein signaling may play a role in the Ca
2+ 
response elicited by the D1R-D2R complex. This was demonstrated by observing 
increased Ca2+ mobilization in response to DA in cells transfected with the D1R and D2R 
plus Gαq. However, we also observed that the D1R alone may couple to Gαq when the 
alpha subunit is expressed in significantly high amounts. This is likely due to the D1R 
having a relatively low affinity for Gαq, however, it may activate Gq-mediated Ca
2+ 
mobilization under conditions where Gq expression is very high. This is also supported by 
the enhanced Ca2+ response we observe when the D1R and D2R are co-expressed in the 
presence of high levels of Gq protein, where the D1R is the protomer within the 
heteromer that likely activates Gαq
103. In this model, it is hypothesized that the D2R 
allosterically modulates the D1R103,132. We believe, however, that the enhanced Ca2+ 
mobilization seen in the D1R+D2R+Gαq transfected cells is not solely due to D1R 
homomer activation of Gq, as the degree of Ca
2+ mobilization (300% of control, Figure 
13A) is twice that seen in the D1R-Gαq transfected cells (Figure 13B). Interestingly, 
another study has also reported D1R-mediated Ca2+ release from internal stores in mouse 
Ltk- cells transfected with the human D1R144, indicating that this is not an event 
particular to our experimental paradigm. Thus, while Gq may play a role in the apparent 
ability of the D1R-D2R heteromer to couple to Ca2+ signaling, this may be dependent on 
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the level of Gq protein expression, either on a total cellular basis, which would thus be 
cell-type dependent, or this signaling may be localized to specific membrane 
microdomains (see below).  
It has also been suggested that SKF83959 may act as a D1R-D2R heteromer 
selective agonist, and it has been used as a putative heteromer selective probe in vivo. 
However, these studies are not without controversy as SKF83959 has a history of unusual 
pharmacology. Undie et al. found that SKF83959 inhibited D1R-stimulated cAMP 
formation and also induced striatal intracellular Ca2+ mobilization in rats and monkeys104. 
It lacked the side effects typical to D1R agonists that stimulate cAMP production but 
paradoxically seemed to cause typical D1R agonist-like behaviors in rats29, and is an 
effective anti-parkinsonian agent in MPTP-lesioned monkeys unresponsive to L-
DOPA106. In our hands SKF83959 did not stimulate a Ca2+ response in cells transfected 
with both the D1R and D2R, despite the fact that it was active in binding to the D1R. In 
fact, it appeared to act as an antagonist of the DA-stimulated Ca2+ response in D1R and 
D2R co-transfected cells. In contrast, when Gαq was over-expressed, SKF83959 
stimulated a Ca2+ response in cells co-transfected with the D1R and Gαq as well as cells 
co-transfected with the D1R, D2R and Gαq. However, we observed that while the D1R 
selective antagonist, SCH23390, completely blocked the SKF83959-stimulated Ca2+ 
response in both transfection conditions, the D2R selective antagonist, sulpiride, was 
ineffective in the D1R and D2R co-transfection condition. This contrasts with sulpiride’s 
ability to completely block DA-stimulated Ca2+ mobilization in the D1R and D2R co-
transfected cells (cf. Figure 10B and Figure 14B). This suggests that SKF83959 is not 
activating the D1R-D2R heteromer, but rather is activating only D1R homomers that 
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exist in the D1R and D2R co-transfected cells. This could be explained by the 
functionally selective, or biased agonism, properties of SKF83959 in that it can 
selectively activate D1R-Gq signaling, provided that there is sufficient Gαq present, but 
our current results do not support its ability to activate the D1R-D2R heteromer.  
 It has also been proposed that D1R-D2R heteromer activation via SKF83959 in 
vivo and in vitro results in increased Ca2+/CaMKIIα levels in the striatum, further 
resulting in enhanced brain-derived neurotrophic factor expression and increased 
neuronal maturation and differentiation97,102,119,120. Given that our experiments indicated 
that SKF83959 could not induce D1R-D2R heteromer selective Ca2+ mobilization in a 
controlled cell environment, we conducted a single-point competition-binding screen 
against an array of forty-three GPCRs and additional signaling proteins (Table 1 and 
Table 2). We observed that SKF83959 demonstrated considerably high affinity for 
multiple receptors and other signaling proteins, and we conducted secondary competition 
binding experiments on the ones for which it showed the highest affinity. Surprisingly, 
SKF83959 showed nanomolar affinities for many different GPCRs including several 
serotonergic, adrenergic, dopaminergic, and muscarinic receptor subtypes (Table 1). 
Interestingly, it has been reported that the SKF83959-induced locomotor and grooming 
responses stimulated in wild-type mice were inhibited in D1R knock-out mice. The 
grooming and locomotor responses were not inhibited in D2R knock-out, Gαq knock-out, 
or catalytically inactive CaMKII knock-in mice78. This, as well as our functional data, 
questions whether or not SKF83959 may be useful as a selective probe to study D1R-
D2R heteromer, or even D1-like receptor signaling in vivo.  
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Our data also suggested that Ca2+ signaling through the D1R-D2R receptor 
complex is largely sensitive to Gi and Gs inhibition by PTX and CTX, respectively. This 
led us to investigate additional hypotheses for the mechanism of D1R-D2R Ca2+ 
signaling. Recently, Kern et al. (2012) showed that the ghrelin receptor could hetero-
oligomerize with the D2R. This heteromer induced Ca2+ release from internal cellular 
stores in a PLC dependent and PTX-sensitive manner, and seemed to require G subunit 
activation. Previous studies have shown that GRK2 can bind to and sequester G 
subunits125 and catalytically inactive GRK2 mutants that retain G binding have been 
used as tools to block G signaling without the complication of added receptor 
desensitization125,126. Our data demonstrated that the catalytically inactive GRK2 K220R 
mutant completely ablated the DA-stimulated Ca2+ response in the D1R and D2R 
transfected cells while GRK2 c-term (a truncated GRK2 protein that only includes the 
G binding domain) largely decreased the Ca2+ response. Since activated G subunits 
can stimulate PLC activity145, our results are consistent with the hypothesis that the DA-
stimulated Ca2+ response significantly involves G activation of PLC. Additionally, the 
N-terminal RGS domain of GRK2 has been shown to facilitate weak GTPase-activating 
protein-like activity on Gq, inhibiting PLC actvation
146,147. This may explain the 
difference in degree of Ca2+ signal inhibition between the GRK2 K220R mutant and the 
truncated GRK2 c-term mutant147. Therefore, the activation of PLC may be Gqα- as well 




Figure 18 represents several hypothetical signaling pathways for D1R-D2R 
receptor- Ca2+ signaling in HEK293 cells. Pathway A represents D1R-D2R heteromer 
activation of Gq leading to Gαq activation of PLC, as has been hypothesized in the 
literature103. Pathway B represents G activation of PLC, where free beta/gamma 
subunits could arise through activation of either Gs, Gi or Gq. Pathway C represents co-
activation of D1R and D2R homomers and cross-talk between Gs and Gi protein-mediated 
downstream signaling pathways ultimately leading to PLC activation. Given that PTX 
and CTX can nearly eliminate the DA-stimulated Ca2+ signaling, we believe that Pathway 
 
Figure 18: Various mechanisms of PLCβ activation that may occur when the D1R and D2R are 




A is largely inoperative in our system under basal conditions. Pathway C could readily 
account for the requirement for dual receptor activation, but the fact that G sequestration 
largely eliminates the DA Ca2+ response would suggest that Pathway B is critically 
important. The PTX/CTX results further implicate Gs or Gi, however, the requirement for 
dual receptor activation in Pathway B is not completely clear. Certainly, additional work 
will be required to answer these questions, however, it is clear from these studies that 
D1R-D2R receptors can dually activate Ca2+ signaling through more than a single 
mechanism. 
One additional consideration for D1R-D2R- Ca2+ signaling, which does not 
necessarily exclude the possibility of heteromer formation, may involve aggregation of 
the two DARs and their associated proteins in lipid rafts. Lipid rafts are a well-known but 
poorly understood platform for modulating certain protein-protein interactions in neurons 
as well as affecting GPCR ligand sensitivity, membrane trafficking, and signaling148–153. 
Lipid rafts would readily enable crosstalk between the D1R and D2R, and could assist in 
the multi-faceted signaling profile of the D1R-D2R receptor complex. In addition, 
differences in lipid raft composition, cell background, and assay detection may explain 
some of the differences observed between our data and the data generated by other 
groups. Despite the seeming complexity of the D1R-D2R receptor signaling mechanisms, 
it may yet be useful to study how synergistic concurrent activation of the D1R and D2R 
may induce effects not seen when either receptor is expressed alone. This can be 
examined by co-expressing mutants of the D1R and D2R which have been reported to be 
unable to form heteromers141, and studying the effect of co-activation on the generation 
of a Ca2+ signal. Additionally, a compound that can selectively bias both receptors 
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towards a conformation that promotes PLC activation may be useful in providing a 
clearer understanding of the DAR system in vivo.  
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Chapter 3: Discovery and Characterization a G protein Biased Agonist 
MLS1547 that Inhibits β-arrestin-2 Recruitment to the D2R 
Background 
Among the DARs, the D2R is one of the most validated drug targets in neurology 
and psychiatry. However, most drugs targeting the D2R are problematic, either being less 
efficacious than desired or possessing adverse side effects due to the activation or 
blockade of multiple parallel signaling pathways. Despite recent advances, it remains 
unclear which signaling arms of the D2R are involved in the therapeutic effects of 
various agents used to treat neuropsychiatric disease states associated with the D2R.  
One of the best characterized signaling pathways of the D2R is Gi/Go-mediated 
inhibition of adenylate cyclase, which reduces intracellular cAMP levels and thereby 
attenuates phosphorylation of the DARPP-32 by PKA154. DARPP-32 is a protein 
phosphatase that acts as an integrator of cell signaling of many neurotransmitters, 
including DA (Figure 4, Figure 5)155. Reduction of DARPP-32 phosphorylation inhibits 
its activity and associated downstream signaling pathways154,155. Notably, administration 
of antipsychotic drugs, such as haloperidol or clozapine, has been shown to increase the 
level of DARPP-32 phosphorylation156.  
A more recently characterized D2R G protein-independent signaling pathway 
occurs through agonist recruitment of -arrestin-2 to the receptor, which inhibits protein 
kinase B (Akt). Typically, regulation of Akt is associated with the insulin and 
neurotrophin pathways. The first link between the D2R and Akt was seen when D2R 
activation caused reduced Akt activity and increased activation of the Akt target glycogen 
synthase kinase 3β (GSK3), while D2R inhibition caused precisely the opposite 
reaction157,158. Additionally, mice that lacked β-arrestin-2 did not show reduced Akt when 
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the D2R was stimulated, pointing to β-arrestin-2 as the intermediary signaling protein 
between the D2R and Akt159. Through further study, it was found that following 
recruitment to the D2R, β-arrestin-2 forms a complex with Akt and protein phosphatase 
2A, which results in dephosphorylation of Akt and subsequent activation of GSK3160,161.  
 
The D2R-β-arrestin-2-Akt signaling occurs at a much slower timescale compared 
to the D2R-G protein signaling162, which could be explained by the hypothesis that G 
proteins may be pre-coupled to GPCRs, while arrestins require receptor activation to be 
recruited to the receptor110. Interestingly, Caron and colleagues have argued that 
inhibition of this pathway in D2R-expressing neurons is correlated with antipsychotic 
properties163,164, whereas Roth and colleagues have suggested that stimulation of the 
D2R-β-arrestin-2 pathway may actually enhance antipsychotic efficacy165,166.  
A promising approach to dissecting the importance of these signaling pathways, 
and resolving associated controversies, is to study them using ligands that exhibit 
functionally selective or biased signaling properties167,168. Many GPCRs are able to 
transduce signals through more than one intracellular pathway. Although in most cases 
the endogenous transmitter will activate all signaling pathways, synthetic agonists may 
 
Figure 19: D2R β-arrestin-2 G protein-independent signaling.  
Protein kinase B (Akt) has classically been associated with the insulin and neurotrophin pathways. 
However, a new pathway has been described wherein the D2R-β-arrestin-2-protein phosphatase 2A 
(PP2A) complex is able to inhibit Akt-mediated inhibition of glycogen synthase kinase 3β (GSK3β). 
Green arrows indicate activation and red lines indicate inhibition. 
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preferentially activate one signaling pathway over another, or even activate one while 
inhibiting another169–171. While the mechanisms underlying functional-selectivity are not 
known, a leading hypothesis is that GPCRs can adopt multiple functionally “active” 
conformational states that are either stabilized or induced by these selective ligands172,173. 
Functionally selective compounds have been reported for many GPCRs and the 
mechanisms for biased signaling vary widely174. Biased signaling units may consist of 
GPCR homomers or require receptor homo- or heteromerization48,117,175. Coming from 
the other direction, biased ligands can bind allosterically175,176, orthosterically165,177, or 
bitopically178,179 and can be small molecules177, large compounds180, or even short peptide 
sequences called pepducins176,181.  
Although relatively few biased ligands have been described for the D2R182–186 
existing examples strongly support the concept of the D2R being able to adopt multiple 
signaling-biased confirmations. Recently, a structural basis for functional-selectivity of 
several GPCRs has been proposed180,187–189 suggesting that rational design of functionally 
selective compounds may be possible. 
Recently, Jin and colleagues developed and characterized a series of analogs of 
the atypical antipsychotic aripiprazole that are partial agonists of D2R-mediated -
arrestin recruitment yet fail to stimulate Gi-linked cAMP inhibition
165,166. Likewise, we 
currently describe the identification of an arrestin biased compound for the D2R (see 
Results). In contrast, no biased ligands had previously been described with the opposing 
pharmacology for the D2R, that is, stimulation of G protein signaling pathways without 
activation of β-arrestin recruitment. In this project, we now report the discovery of a 
novel, highly efficacious G protein biased agonist for the D2R with no detectable β-
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arrestin-2 recruitment to the receptor. Identification of such functionally selective ligands 
may provide the requisite pharmacological probes with which to dissect these two 
signaling pathways and elucidate their function in vivo. Functionally selective agonists 
may also result in improved therapies for certain neuropsychiatric disorders, such as 
Parkinson’s disease (in which D2R stimulation is desired) and schizophrenia (where 
inhibition of D2R signaling is the goal).  
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Materials and Methods 
Ca2+ mobilization Assay – Flp-In T-Rex 293 cells were stably transfected with human 
D2SR and Gqi5 protein using the Flp-In T-Rex expression system (Life Technologies, 
Grand Island, NY). The cell line was constructed by co-transfecting SFD2s/FRT/TO and 
pOG44, followed by hygromycin B selection. Gqi5/pIRESpuro3 (Clontech) was then 
transfected into the D2R stable cell line, followed by selection with puromycin. D2R 
expression is controlled by tetracycline induction, while Gqi5 is continuously expressed. 
D2R-stimulated Ca2+ mobilization was measured using methods similar to those 
previously published by our laboratory42 and in Chapter 2. Cells were induced with 1 M 
tetracycline added directly to the culture media and plated in as described in Chapter 2 in 
384- or 1536-well, optical, clear bottom, black-walled plates (Greiner Bio-one, Monroe, 
NC). 20 μL/well (20,000 cells/well) were added to 384-well plates, and 3 L/well (4,000 
cells/well) to a 1536-well plate. See Chapter 2 Materials and Methods for the procedure 
following plating. 
 
cAMP Inhibition Assay – D2R-mediated inhibition of forskolin-stimulated cAMP 
production was assayed using the DiscoveRx HitHunter assay kit (DiscoveRx Inc., 
Fremont, CA). CHO-K1 cells stably expressing the human D2R long isoform 
(DiscoveRx) were seeded in CP2 media at a density of 5,000 cells/well in 384-well black, 
clear-bottom plates. After 16-24 h of incubation at 37°C, 5% CO2, and 90% humidity, the 
media was removed and replaced with 5 μl / well PBS. Cells were treated with 2.5 μl of 
various concentrations of compound diluted in PBS in the presence of an ~EC80 
concentration of forskolin (100 μM) and 0.2 mM sodium metabisulfite and incubated for 
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60 min at 37°C, 5% CO2, and 90% humidity. DiscoveRx HitHunter reagents were then 
added, and cells incubated in the dark at room temperature, according to manufacturer 
recommendations. Luminescence was measured on a Hamamatsu FDSS μCELL 
(Hamamatsu Photonics K. K., Bridgewater, NJ) for 8.5 sec. Data were collected as RLUs 
and values were normalized to a percentage of the maximum forskolin-stimulated cAMP 
signal. Data fit to a single site model and the Hill coefficients of the concentration 
response curves did not significantly differ from unity. 
 
β-Arrestin Recruitment Assay – The ability of the agonist-activated receptor to recruit β-
arrestin-2 was determined using the DiscoveRx PathHunter (DiscoveRx Inc., Fremont, 
CA) technology that involves enzyme complementation of fusion-tagged receptor along 
with an arrestin recruitment modulating sequence and β-arrestin-2 proteins. Control 
experiments determined that this PathHunter receptor construct will couple to G protein-
mediated signaling with similar efficacy as an unmodified construct (data not shown). 
Assays were conducted, with minor modifications, as previously published by our 
laboratory190,191. Briefly, CHO-K1 cells expressing D2R long isoform (DiscoveRx) were 
seeded in CP media (DiscoveRx) at a density of 2,625 cells/well in 384-well black, clear-
bottom plates. Following 24 h of incubation, the cells were treated with multiple 
concentrations of compound in PBS containing 1% DMSO and incubated at 37˚C for 90 
min. DiscoveRx reagent was then added to cells according to the manufacturer’s 
recommendations followed by a 30-60 min incubation at room temperature. 
Luminescence was measured on a Hamamatsu FDSS μCELL reader (Hamamatsu, 
Bridgewater, NJ). Data were collected as relative luminescence units (RLU) and 
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subsequently normalized to a percentage of the control luminescence seen with a 
maximum concentration of DA, with zero percent being RLU seen in the absence of any 
compound. The Hill coefficients of the concentration response curves did not 
significantly differ from unity. 
 
β-Arrestin-2 BRET Assay – To directly assess induction of D2R--arrestin-2 interaction 
we employed a bioluminescence resonance energy transfer (BRET) assay that utilizes a 
cell line stably transfected with an Rluc-8 fusion-tagged D2R (short isoform) under a 
tetracycline-inducible promoter, as well as mVenus fusion-tagged -arrestin-2192,193. The 
cell line was constructed using Flp-In T-REX 293 cells (Invitrogen, Life Technologies) 
transfected with pIRESpuro3/mVenus/-arrestin-2, where the mVenus tag is on the N-
terminus of the human -arrestin-2. Clones were then analyzed for expression of the 
construct following selection with 2 µg/ml puromycin. The cell line with the highest level 
of expression was then transfected with pcDNA5/FRT/TO-SFD2LRluc8 and POG44 
followed by hygromycin selection and subsequent functional screening to select the final 
stable line. Addition of the Rluc-8 substrate coelenterazine h results in an emission at 485 
nm. However, when in close proximity with mVenus, resonance energy transfer leads to 
a shift in the emission spectrum from 485 nm to 510-540 nm, thereby quantifying the 
interaction between the receptor and the β-arrestin-2 protein. Cells were induced for 24 h 
by addition of 1 M tetracycline directly to the culture media resulting in membrane 
receptor expression of approximately 5.8 pmol/mg protein. Cells were then removed 
from the plates using Earle’s balanced salt solution without Ca2+ (EBSS-), pelleted by 
centrifugation, re-suspended (200,000 cells/ml) in Dulbecco’s Phosphate Buffered Saline 
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(DPBS) (Mediatech, Manassas, VA) plus 0.05 g/500 ml sucrose and seeded into 96-well 
solid bottom white assay plates (20,000 cells/well) (Greiner Bio-one, Monroe, NC). Cells 
were allowed to sit for 45 min at room temperature and were then treated with 5 M 
coelenterazine h (Nanolight Technology, Pinetop, AZ), incubated for 5 min and then 
stimulated with agonist using an onboard robotics 8 channel pipet head in a Flexstation 
III (Molecular Devices, Sunnyvale, CA). Original data are collected 5 min after agonist 
addition as a ratio of 525nm/485nm emission. Data are expressed as normalized to the 
percentage of the maximum DA-induced ratio. 
 
Radioligand Binding Assays – Radioligand competition binding assays were conducted 
with slight modifications as previously described by our laboratory42. HEK293 cells 
stably transfected with human D1R, D2R, D3R, D4R, or D5R (Codex Biosolutions, Inc., 
Gaithersburg, MD) were dissociated from plates using EBSS-, and intact cells were 
collected by centrifugation at 900  g for 10 min. Cells were re-suspended and lysed 
using 5 mM Tris-HCl and 5 mM MgCl2 at pH 7.4 at 4°C. Cell lysate was pelleted by 
centrifugation at 30,000 × g for 30 min and re-suspended in EBSS with Ca2+ at pH 7.4. 
Cell lysates (100 l, containing ~8 g protein for D2-like receptor assays or ~10 g 
protein for D1-like receptor assays) were incubated for 90 min at room temperature with 
the indicated concentrations of MLS1547 and either 0.5 nM [3H]-SCH23390 (D1R and 
D5R), or 0.5 nM [3H]-methylspiperone (D2R, D3R, and D4R) in a final reaction volume 
of 250 μl. Non-specific binding was determined in the presence of 4 μM (+)-butaclamol. 
Bound ligand was separated from free by filtration through a PerkinElmer Unifilter-96 
GF/C 96 well micro-plate using the PerkinElmer Unifilter-96 Harvester, washing 3 times, 
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1 ml per well in ice-cold assay buffer. After drying, 50 μl of liquid scintillation cocktail 
(MicroScint PS, Perkin Elmer, Waltham, MA) was added to each well, plates were 
sealed, and analyzed on a PerkinElmer Topcount NXTTM.  
 
Pharmacophore Modeling – All modeling was performed using tools in the Schrödinger 
suite (Schrödinger Inc., New York, NY). While the main goal of pharmacophore 
modeling is to explain the molecular features that are associated with active compounds, 
such capability can benefit from the inclusion of “inactive” compounds in the model 
building procedure. In our case, to differentiate G protein biased from non-biased 
agonists in such a model we defined a so called “biased activity” measure that is similar 
to the “bias factor”194, but without taking the exponential form:  
 
For G protein biased agonists that did not exhibit measurable β-arrestin-2 stimulation, we 
assigned an Emax of 5% and an EC50 of 1 mM in order to generate bias factors, via the 
above equation, that can be compared to those for less biased agonists. Our rationale for 
selecting these values is that the β-arrestin-2 assay cannot reliably detect a signal of 5%, 
or less, over basal and 1 mM is 10-fold higher than the maximum concentration tested for 
any compound. Notably, the log10(Emax/EC50) values from the G protein assay drive the 
ranking of these fully biased ligands.  
Based on this “biased activity” measure, ten compounds, displaying either the 
strongest or weakest G protein-bias were selected: NCGC9125, NCGC9126, NCGC6387, 
NCGC9141 and MLS1547 for the biased set, and NCGC9134, NCGC9132, NCGC5872, 
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NCGC9131 and NCGC6388 for the non-biased set (see Results). For each compound, the 
3D structure was built using the program Maestro (v9.5), and a single protonation state 
was chosen, with the 4-position of the piperazine bearing the positive charge in all cases. 
Multiple conformers were generated using the ConfGen program (v2.5). At least 10 
conformers per ligand were generated, which required sampling with the “intermediate” 
search strategy of the program.  
The goal of a pharmacophore search is to identify the largest set of 
pharmacophore features with specific 3-dimensional relationships, i.e., inter-feature 
distances that are common amongst all active compounds. The pharmacophore model 
was built using the program Phase (v3.6). The default pharmacophore features include 
positive (P), negative (N), hydrogen-bond acceptor (A), hydrogen-bond donor (D), 
aromatic (R) and hydrophobic (H) types. For the compounds studied here, the following 
functional groups were assigned to the hydrophobic (H) feature using a procedure that 
has been described by Green et al.195: isopropyl, aromatic halogens, aromatic CH3, and 
methoxy-CH3. The location of a given hydrophobic site is a weighted average of the 
positions of the non-hydrogen atoms in the associated fragment.  
In addition, to allow ambiguous alignment of non-polar features, aromatic groups 
in the ligands were assigned to both the R and H feature types. When we assigned these 
features to the selected ligands, the largest number of features in a pharmacophore 
hypothesis that produced matches for all 5 biased compounds was found to be 4. These 4-
point pharmacophores were of the HHPR, AHHP, HPRR and AHPR variants (the order 
of the features is arbitrary). For each of these variants, a number of 3D hypotheses were 
enumerated and clustered based on all occurring inter-feature distances. From this initial 
57 
 
set of hypotheses, the one that best matched the active compounds was then determined 
by a more rigorous custom scoring function (“survival score”), which consisted of 1) the 
alignment score based on the RMSD of feature positions, 2) the vector score of aligned 
features with a directional character (aromatic, donor and acceptor), and 3) the pairwise 
volume overlap of all the ligands aligned to the pharmacophore. This default scoring of 
all possible variants revealed that the HHPR and HRPR hypotheses were best able to 
explain the data. To eliminate the hypotheses that also matched the non-biased 
compounds, the 5 most non-biased compounds were used to rescore the hypotheses 
(“inactive score”). The finally selected pharmacophore was the HRPR variant (see 
Results) with the best “survival”-“inactive” score. 
 
Construction of a novel active D2R model – Our active D2R model was based on an 
active model of the D3R, for which an inactive crystal structure is available13. The active 
D3R model was created by applying a set of spatial constraints obtained by comparing 
the inactive and active states of the 2 adrenergic receptor (2AR). In brief, the inactive 
and active structures of the 2AR (PDB: 2RH1196 and PDB: 3SN6197 respectively) were 
aligned and, by subtracting the coordinates of the C atoms of the inactive from the 
active form, a set of delta-coordinates were created. These deltas were added to the 
coordinates of the aligned D3R structure to generate a set of spatial constraints. Using 
these constraints, the inactive model of the D3R was transformed into an active form by 
using a hybrid minimization-Monte Carlo scheme, implemented in the program Prime 
(v3.3). The active D3R model was then used as a template in building the D2R homology 
model using Prime. Docking of compounds into the active-state model of the D2R was 
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achieved using the program Glide (v6.0), using the SP scoring function. To determine the 
binding mode of the congeneric series, a single reference compound (MLS1547) was first 
docked in the orthosteric binding site (OBS) revealed by the bound eticlopride in the D3R 
structure, which is formed by residues from TMs 3, 5, 6, and 7. We found the pyridine 
moiety of MLS1547 preferred to point towards TM2. Interestingly, for two well-studied 
D2R antagonists, spiperone and azaperone that share a common 4-fluophenyl-4-butanone 
moiety, as proposed/validated previously198, if we assume that such a moiety is bound in 
the OBS, then the pyridine moiety of azaperone similarly points towards TM2 as 
MLS1547 (data not shown). We also docked MLS1547 in another D2R model in an 
active conformation based on a D3R active model199 and equilibrated using MD 
simulations. Encouragingly results from both D2R models were consistent. All other 
compounds were then docked using core-constraints on the core substructure shared by 




In an effort to discover G protein biased agonists of the D2R, we screened a 
~380,000 compound small molecule library in the Molecular Libraries Probe Production 
Center Network (MLPCN) at the National Center for Advancing Translational Sciences 
(NCATS) (Figure 20). The primary screen used a stably transfected cell line expressing 
the human D2R and a chimeric Gqi5 protein enabling robust Ca
2+ mobilization upon 
activation of the D2R. This screen identified 2,288 compounds with significant D2-Gqi5 
agonist activity, defined as compounds that, when screened at 40 M, elicited a response 
larger than 3-fold over the standard deviation of mean signal from control wells with no 
compound. Agonists were also screened for Ca2+ mobilization in parental, non-
transfected cell line and any compound showing activity was eliminated. The active 
compounds were then subjected to verification by generating full concentration-response 
curves for each compound. Subsequently, the hit compounds that exhibited full dose-
response-activity relationships were evaluated in two orthogonal assays - one was to 
evaluate their ability to inhibit cAMP accumulation, a primary G protein signaling 
mechanism for the D2R154, and the other was to test their ability to recruit -arrestin-2, an 




As would be expected, our results revealed that the vast majority of the hit 
compounds were equally active in both the G protein- and -arrestin-2-mediated 
signaling assays (see Figure 21). However, a small subset of hits (about two dozen) 
showed either greatly diminished efficacy and/or potency in the -arrestin-2 recruitment 
assay. One of these compounds, MLS000051547 (MLS1547, Figure 22A), was selected 
for further characterization as it appeared to have high efficacy in the G protein-mediated 
signaling assays, but no measurable activity in the -arrestin-2 recruitment assay.  
 
Figure 20: Flowchart of D2R G protein biased ligand screen. 
Abbreviations: CRC (concentration response curve), HTS (high-throughput screen), MLS1547 






Figure 21: Examples of compounds with little to no bias between G protein- and β-arrestin-2-
mediated signaling.  
Compounds were assayed for agonist activity in both D2R-mediated inhibition of cAMP and D2R-
mediated arrestin recruitment assays. Results were normalized to 100% maximum dopamine response 
for each group. A: NCGC00124006 was screened as an agonist in both assays giving Emax values of 
80.5% in the cAMP inhibition assay and 69.9% in the arrestin recruitment assay. Corresponding EC50 
values were 0.29 and 0.39 μM in the cAMP inhibition and arrestin recruitment assays, respectively. B: 
NCGC00138930 was screened as an agonist in both assays giving Emax values of 99.3% in the cAMP 
inhibition assay and 100.4% in the arrestin recruitment assay. Corresponding EC50 values were 0.04 μM 
and 0.02 μM in the cAMP inhibition and arrestin recruitment assays, respectively. Data are 
representative graphs from screening assays. Dopamine was run as a non-biased control and mean 




Indeed, Figure 22B shows that MLS1547 behaved as a highly efficacious agonist 
in the D2-Gqi5 Ca
2+ mobilization assay with an EC50 value of 0.37 M and an Emax of 
~90%. In order to insure that this activity is physiological, and not restricted to the 
chimeric G protein nature of the Gqi5 assay, we examined the ability of MLS1547 to 
inhibit forskolin-stimulated cAMP accumulation in cells stably expressing the D2R. 
Figure 22C shows that, similar to DA, MLS1547, completely inhibited the stimulation of 
cAMP by forskolin with an EC50 of 0.26 M suggestive of it having high efficacy at 
 
Figure 22: MLS1547 stimulates D2R G protein-mediated signaling.  
A: Structure of MLS000051547 (MLS1547). B: HEK293 cells stably expressing D2R and Gqi5 were 
assayed for MLS1547 stimulation of Ca2+ accumulation. Cells were stimulated with the indicated 
concentrations of dopamine or (EC50=2.5 nM  0.3, Emax=101.7%  0.1) or MLS1547 (1547) 
(EC50=0.37 M  0.2, Emax=89.3%  4.3) C: CHO cells stably expressing the D2R were assayed for 
MLS1547 inhibition of forskolin-stimulated cAMP. Cells were stimulated with the indicated 
concentration of dopamine (EC50=0.06 M  0.02, Emax=100.4%  1.6) or MLS1547 (EC50=0.26 M  
0.07, Emax=97.1%  3.7). D: CHO cells stably expressing D2R were assayed for sulpiride reversal of 
MLS1547 inhibition of forskolin-stimulated cAMP accumulation. Cells were stimulated with an EC80 
concentration of MLS1547 in the presence of increasing concentrations of the D2R antagonist sulpiride 
(IC50=22.0 nM  2.8). Data are representative of 3-5 independent experiments run in triplicate and 
plotted as a percentage of the maximum response observed with dopamine (B and C), or as a 
percentage of the response seen with an EC80 concentration of MLS1547 (D), as indicated. 
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D2R-mediated G protein-linked signaling. We further found that the inhibition of cAMP 
accumulation by MLS1547 was completely blocked by co-treatment with the D2R 
antagonist sulpiride, as shown in Figure 22D. The IC50 of 22 nM for sulpiride’s inhibition 
of MLS1547’s action is similar to sulpiride’s potency for blocking DA’s response in this 
cAMP assay (data not shown). Taken together, these data indicate that MLS1547 is a 
highly efficacious agonist at the D2R for stimulating G protein-mediated signaling. 
The ability of MLS1547 to stimulate recruitment of -arrestin-2 to the D2R was 
evaluated using the DiscoveRx -arrestin-2 PathHunter assay, which relies on the 
complementation and activation of β-galactosidase when -arrestin-2 is recruited to the 
receptor. Notably, -arrestin-2 is the arrestin protein functionally coupled to the D2R in 
vivo200. While incubation with DA resulted in robust recruitment of -arrestin-2 in a 
dose-dependent manner, MLS1547 failed to exhibit activity in this assay (Figure 23A) 
despite it being a highly efficacious agonist of G protein-mediated signaling. However, 
other possible explanations for these discrepant results could include interference of the 
compound with the enzyme-linked signaling resulting in a suppression of signal. To 
address these alternative explanations, we employed a bioluminescence resonance energy 
transfer (BRET) assay that directly measures the physical interactions between the β-
arrestin-2 protein and the D2R. Furthermore this also serves as a control for a different 
cell background, as these assays were conducted in HEK293 cells. As seen in Figure 
23B, however, MLS1547 failed to stimulate any observable recruitment of -arrestin-2 to 
the D2R in this assay, despite robust recruitment by DA. Taken together, these findings 
indicate that, while MLS1547 is a highly efficacious agonist at G protein-mediated 
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signaling, it is unable to stimulate measurable -arrestin-2 recruitment, thus establishing 
it as a highly G protein biased agonist at the D2R. 
 
Since MLS1547 activates G protein-linked pathways, yet does not appear to 
stimulate -arrestin-2 recruitment, MLS1547 would be expected to antagonize the DA-
induced -arrestin-2 response by blocking DA binding to the receptor. In fact, as seen in 
 
Figure 23: MLS1547 acts as an antagonist for dopamine-stimulated β-arrestin-2 recruitment to 
the D2R.  
A: DiscoveRx PathHunter cells were assayed for agonist-induced recruitment of -arrestin-2 to the 
D2R. Cells were stimulated with the indicated concentrations of dopamine or MLS1547 (1547), and 
EC50 and Emax values were obtained for dopamine, 0.09 M  0.03 and 99.0%  0.6, respectively (mean 
 SEM, n=3). MLS1547 failed to stimulate measurable -arrestin-2 recruitment. B: HEK293 cells were 
stably transfected with Rluc-8-fused D2R and mVenus-fused -arrestin-2, stimulated with various 
concentrations of dopamine (EC50=0.05 M  0.01, Emax=99.8%  1.9) or MLS1547 (1547) as 
indicated, and examined for BRET as described in the Materials and Methods. MLS1547 failed to 
stimulate any measurable D2R--arrestin-2 interactions. Data for panels A and B are representative of 
3-5 independent experiments run in triplicate and plotted as a percentage of maximum response 
observed with dopamine as indicated. C: DiscoveRx PathHunter cells were stimulated with an EC80 
concentration of dopamine (1 µM), then assayed for the ability of MLS1547 to antagonize this response 
(IC50=9.9 M  0.9). Data are expressed as the percentage of the maximum response observed with 1 
M dopamine and represent the mean  SEM values of three individual experiments performed in 
triplicate. D: The same cells described for the BRET assay in B above were stimulated with an EC80 of 
dopamine (1 M) and assayed for the ability of MLS1547 (IC50=3.8 M  1.8) to antagonize this 
response. Data are expressed as mean  SEM of six independent experiments run in quadruplicate.  
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Figure 23C, MLS1547 fully antagonized DA-mediated -arrestin-2 recruitment to the 
D2R in the DiscoveRx assay, with an IC50 of 9.9 M. Similar results were obtained when 
MLS1547 was examined for antagonist activity in the D2R -arrestin-2 BRET assay, 
demonstrating an IC50 of 3.8 M (Figure 23D). In summary, while MLS1547 is an 
agonist of D2R-stimulated G protein-mediated signaling, it does not stimulate -arrestin-
2 recruitment to the receptor, instead acting as an apparent antagonist of DA-mediated -
arrestin-2 recruitment. 
In order to determine the affinity of MLS1547 for the D2R, we used standard 
radioligand binding competition analyses. MLS1547 was found to completely displace 
[3H]-methyl-spiperone binding to the D2R with a calculated Ki value of 1.2 M  0.2 
(Figure 24). Displacement studies were also conducted on the other DA receptor subtypes 
(Figure 25) resulting in Ki values of 2.3 M  0.2 (D3R) and 0.32 M  0.04 (D4R), 
mean  SEM (n=3), suggesting a less than 10-fold difference in affinity between the 
members of the D2-like family. When the D1-like receptors were examined by measuring 
the ability of MLS1547 to displace [3H]-SCH23390 binding to D1 and D5 receptors, the 





A series of MLS1547 analogs were either obtained from commercial sources, or, 
in a few cases, synthesized to investigate the structure-activity relationship (SAR) of 
pathway selectivity for this set of compounds. These analogs were assayed in the D2R 
DiscoveRx cAMP assay as well as in the D2R DiscoveRx -arrestin-2 recruitment assay 
(Table 3 and Table 4) Although none of the analogs were more potent than MLS1547, a 
 
Figure 24: Competition binding assay using MLS1547 and the D2R.  
Membranes from HEK293 cells stably transfected with the human D2R were harvested for radioligand 
competition binding assays as described in the Materials and Methods. Membranes were incubated with 
the indicated concentrations of MLS1547 and 0.5 nM [3H]-methylspiperone. The data are 
representative of four independent experiments and expressed as a percentage of the binding seen in the 
absence of any competing ligand. The Ki for MLS1547 was calculated to be 1.2 M ± 0.2 (mean  
SEM, n=4). 
 
Figure 25: Competition binding of MLS1547 for dopamine receptor subtypes.  
Membranes from HEK293 cells stably transfected with human D1R, D3R, D4R, or D5R (Codex 
Biosolutions, Inc., Gaithersburg, MD) were harvested for radioligand competition binding. Briefly, 
membranes were incubated with the indicated concentrations of MLS1547 and either 0.5 nM [3H]-
SCH23390 (D1R and D5R), or 0.5 nM [3H]-methylspiperone (D3R and D4R). The curves shown are 
representative of four independent experiments done on different days. Data are expressed as a 
percentage of the binding seen for each individual receptor subtype in the absence of any competing 
ligand. Ki values were calculated using the Cheng-Prusoff equation and radioligand Kd values 
determined via saturation binding isotherms on each individual receptor. Average Ki values are reported 
in the Results section. 
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subset of the analogs were also G protein biased in that they inhibited cAMP 
accumulation yet lacked -arrestin-2 recruitment activity (Table 3). However, another 
subset of compounds exhibited agonist activity in both the cAMP and -arrestin-2 assays 
with little to no bias (Table 4). These findings were used to formulate a preliminary SAR 
of G protein bias in this series of compounds.  
 
To do this, a pharmacophore model was constructed to distinguish between the 
highly G protein biased (Table 3) and less/non-biased D2R agonists (Table 4). 
Specifically, we selected ten compounds, displaying either the strongest or weakest G 
 
 
Figure 26: Pharmacophore model for G protein biased and non-biased agonist interactions with 
the D2R.  
A and B: HRPR pharmacophore with aligned biased compounds MLS1547 and NCGC9141. Biased 
compounds align well to all four features: two aromatic (beige), one hydrophobic (green) and a positive 
(blue) feature. Middle: Compared to the biased compound MLS1547, the non-biased compound 
NCGC5872 (left) lacks the -Cl group and cannot align both the hydrophobic and aromatic features, 
while the different attachment points of the naphthalene ring in compounds NCGC9141 and 
NCGC5873 cause the former, but not the latter to align well to the 4-point pharmacophore. In this case, 
one of the aromatic rings in NCGC9141 aligns the hydrophobic feature. C and D: docked poses of 
biased (cyan) and unbiased (grey) compounds in an active model of the D2R. Note the more extensive 
interaction of non-polar features in the biased compounds with a hydrophobic pocket formed by 




protein-bias, and then assigned default pharmacophore features (positive (P), acceptor 
(A), donor (D), aromatic (R) and hydrophobic (H)) to these ligands (see Methods). We 
found that a 4-point HRPR hypothesis was best able to explain the experimental data 
(Figure 26A and B). Specifically, the alignment of the “H” feature in these compounds is 
the key difference between the completely biased (Table 3) and less/non-biased (Table 4) 
agonists of this scaffold. As shown by two representative biased/non-biased pairs in 
Figure 26, the completely biased compounds align optimally to the “H” feature, whereas 
the less/non-biased compounds do not (Figure 26A and B). 
In parallel, we docked these compounds into a novel active-state model of the 
D2R using MLS1547 as a reference compound. For the MLS1547 compound, we 
observed two plausible orientations with the pyridine moiety pointing towards either 
TM5 in the orthosteric binding site (OBS) or toward TMs 2 and 7, away from the OBS 
(data not shown). Based on the SAR derived from Table 3, it appears that the N in the 
pyridine ring likely makes an H-bond with a receptor residue, as there is a ~10 fold 
increase in the potency of MLS1547 compared to that of NCGC319125. When the 
pyridine points towards TM5, however, a corresponding H-bond donor cannot be 
identified in the OBS. Thus, it is more likely that MLS1547 adopts the alternate 
orientation with the pyridine pointing toward TMs 2 and 7, in which the N on the 
pyridine ring may interact with T412 in TM7 to form an H-bond. These docking results 
were confirmed using a model with the D2R in an active conformation based on another 
D3R active model199 and equilibrated using molecular dynamics simulations (data not 
shown). Encouragingly, results from both models were similar. 
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Using the MLS1547 pose with the pyridine pointing toward TMs 2 and 7, we 
used a core-restrained protocol to dock the other compounds into the active D2R model 
in order to compare the binding modes of the fully G protein biased vs. less/non-biased 
agonists. The resulting poses show that the completely biased compounds from Table 3 
have a significantly higher tendency to interact with the extracellular portion of TM5. 
Specifically, the chloro (-Cl) group of MLS1547 interacts with a hydrophobic pocket 
formed by Ile184EL2, Phe1895.38, and Val1905.41 (Figure 26).  
Interestingly, this is consistent with our finding from the pharmacophore 
modeling that the fully G protein biased, but not the less/non-biased compounds, can be 
well-aligned to the “H” feature of the aforementioned HRPR pharmacophore. While 
recent publications suggest a possible role for aromatic -Cl groups in an H-bond 
formation, it is not atypical to consider -Cl as a hydrophobic group as well. Indeed, there 
are multiple examples in the literature where a methyl/-Cl swap resulted in roughly the 





Table 3: Analogs of MLS1547 exhibiting complete G protein bias.  
The compounds were assayed in agonist mode using the DiscoveRx cAMP and arrestin assays. 















(M  SEM) 
 
MLS1547 97.1  3.7 0.26  0.07 Inactive Inactive 
 
NCGC00319124 87.3  14.7 5.5  0.9 Inactive Inactive 
 





66.8  3.9 2.8  1.2 Inactive Inactive 
 





89.5  5.2 0.7  0.7 Inactive Inactive 
 
MLS000860449 84.9  2.7 4.5  3.0 Inactive Inactive 
 
NCGC0319129 74.8  23.8 9.5  5.6 Inactive Inactive 
 
NCGC00319126 62.8 ± 7.7 1.1 ± 0.6 Inactive Inactive 
 





Table 4: Partially or non-biased analogs of MLS1547.  
The compounds were assayed in agonist mode using the DiscoveRx cAMP and arrestin assays. 
  D2R cAMP Response D2R -arrestin Recruitment 














NCGC00319139 95.5 ± 2.0 0.03 ± 0.01 89.3  9.4 2.0  0.5 
 
NCGC00319137 84.1 ± 4.5 0.02 ± 0.001 84.7  2.5 1.6  0.3 
 
NCGC00319136 93.8 ± 1.4 0.1  0.04 76.4  2.9 0.7  0.07 
 
NCGC00092785 77.0 ± 10.9 0.04 ± 0.01 73.8  1.2 0.4  0.02 
 
NCGC00319134 86.1 ± 14.4 0.1 ± 0.04 74.7  1.8 0.3  0.03 
 
NCGC00319131 89.6 ± 0.5 0.2 ± 0.1 66  0.2 0.8  0.01 
 
NCGC00319132 78.9 ± 10 0.1 ± 0.01 59.2  4.2 0.3  0.04 
 
NCGC00319133 86.5 ± 14.7 0.01 ± 0.001 87.6  2.0 0.2  0.03 
 
NCGC00319130 71.0 ± 17.1 0.1 ± 0.02 66.0  0.2 2.1  0.4 
 
NCGC00319135 83.3 ± 14.4 1.4  0.1 68.9  4.9 13.2  6.6 
 







Table 4, continued: Partially or non-biased analogs of MLS1547. The compounds were assayed in 
agonist mode using the DiscoveRx cAMP and arrestin assays. 
  D2R cAMP Response D2R -arrestin Recruitment 

































93.1 ± 1.6 0.1  0.07 63.3 ± 8.9 0.9  0.6 
 





Preceding this study, no G protein biased D2R ligands had been reported. Here 
we report the discovery of a highly G protein biased D2R agonist (MLS1547) that 
inhibits arrestin recruitment to the receptor (Figure 22, Figure 23). In lieu of attempting to 
rationally design a biased compound based on known D2R ligands, a high throughput 
screen was implemented which led to the detection of MLS1547. We then used chemical 
analogs of MLS1547 to identify SAR that led to the development of a model for biased 
D2R signaling (Figure 26).  
One of the key difficulties involving functionally selective ligands is how exactly 
to characterize and quantify the degree of signaling bias174,194,202,203. In the simplest terms, 
one must take both signaling potency and efficacy of all associated signaling cascades 
into account to determine bias. Additionally, in some cases, different signaling cascades 
may have completely different spatio-temporal characteristics162, further complicating the 
determination of ligand bias. One group has developed a mathematical formula to 
determine a ligand’s “bias factor”194. We used the bias factor formula without the 
exponential form to calculate “bias activity”, as described in the Materials and Methods. 
Using this bias activity measure, five of the most biased compounds (NCGC9125, 
NCGC9126, NCGC6387, NCGC9141 and MLS1547) were compared to five of the least 
biased compounds (NCGC9134, NCGC9132, NCGC5872, NCGC9131 and NCGC6388) 
to develop the pharmacophore model. 
 It is tempting to speculate that the structural basis for the different efficacies of 
these two groups of agonists critically depends on whether a compound can interact with 
the hydrophobic pocket near the extracellular portion of TM5 mentioned above. 
Interestingly, interactions with the extracellular portion of TM5 have previously been 
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proposed as the structural basis for the arrestin signaling bias of the serotonergic agonist 
ergotamine at the 5-HT2B receptor, whereas ergotamine is notably non-biased at the 
related 5-HT1B receptor180. Thus, comparing crystal structures of ergotamine bound to 
both receptors, it was found that the extracellular portion of TM5 is tilted significantly 
more towards the OBS in the 5-HT2B receptor, compared to the 5-HT1B receptor180. 
This suggests a mechanism whereby agonists that prevent such a tilting would bias 
towards G protein activation, compared to the arrestin pathway. Future experiments to 
test this SAR prediction for the D2R and other GPCRs will be required. It is interesting to 
note, however, that in the D2R, mutations of four residues at the cytoplasmic end of TM5 
disrupt arrestin recruitment much more than they impact cAMP signaling204, suggesting 
that differential propagation of signals through TM5 may play an important role in 
determining signaling bias. Interestingly, several D2R mutants with mutations in the third 
transmembrane domain were described which were either G protein biased or arrestin 
biased when stimulated with DA205.  
In summary, MLS1547 is the first example of a G protein biased agonist of the 
D2R. While it robustly activates G protein-mediated signaling, the compound does not 
appear to significantly promote arrestin recruitment to the receptor. Rather, through 
occupancy of the receptor, MLS1547 functions as an apparent antagonist of DA-induced 
arrestin recruitment to the D2R. Administration of compounds with this pharmacological 
profile to animals would be expected to stimulate G protein biased signaling of the D2R 
while simultaneously inhibiting the effects of endogenous DA signaling through the β-
arrestin-2/Akt/GSK3β pathway. Such compounds may also engender less arrestin-
mediated receptor desensitization or internalization, thereby further amplifying the G 
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protein signaling arm. Recently, β-arrestin biased agonists have been developed for the 
D2R that exhibit varying degrees of agonist efficacy165,166. Functionally selective probes 
for both of the major signaling arms of the D2R should now help to dissect their roles in 
normal physiology and behavior as well as elucidate their involvement in the therapeutic 
effects of various pharmaceutical agents.  
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Chapter 4: SAR Investigation MLS1547 and its Analogs Reveals 
Molecular Signatures Essential for Compound Bias 
Background 
Most agonists, in particular the endogenous neurotransmitter will typically 
activate all associated signaling pathways in parallel with equal or similar efficacy. 
However, it is now recognized that some agonists may be functionally selective, resulting 
in a variety of possible downstream signaling configurations206. In Chapter 3, the 
discovery of a G protein biased D2R agonist (MLS1547) was described and data that was 
obtained from structurally similar analogs was used to generate a pharmacophore model 
to explain how this molecular scaffold engenders signaling bias.  
Here, MLS1547 signaling is studied further by determining its ability to induce 
receptor internalization. As a G protein biased D2R agonist, it is expected that little to no 
D2R internalization would be stimulated by MLS1547. Indeed, G protein biased ligands 
for other GPCRs have shown a lack of receptor internalization despite the activation of 
other parallel signaling cascades207,208. Here, we show that D2R stimulation by MLS1547 
shows a marked lack of receptor internalization compared to non-biased agonist, yet this 
may be dependent on the cellular context. 
To refine and build on the pharmacophore model (Figure 26), additional SAR 
data was obtained through an iterative chemical synthesis approach. 46 distinct analogs 
were synthesized and tested for G protein and β-arrestin-2 signaling activity. Data from 
these new MLS1547 analogs were combined with data for analogs in Chapter 3 to deduce 
the influence of different areas of the scaffold on dictating receptor signaling bias. These 
findings enhance our understanding of biased signaling interactions, refine the existing 
77 
 
model of MLS1547 signaling, and may have implications for the development of 
functionally selective compounds for the D2R. 
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Materials and Methods 
Materials – Original screening quantities of MLS1547 was obtained from the Molecular 
Libraries Screening Center Network Library and subsequently purchased from MolPort 
(Riga, Latvia), for follow-up triage studies. Subsequent batches of the compound were 
synthesized along with all analogs in house at the Kansas Specialized Chemistry Center, 
as described below. Compounds were tested in-house via NMR to confirm purity (>99%) 
and structural accuracy. Identical results were obtained with all batches from all 
suppliers. All other chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless 
otherwise indicated within the methods. All tissue culture media, selection agents, and 
components were obtained from Mediatech, Inc. (Manassas, VA). 
 
cAMP inhibition assay – Assays were performed essentially as previously described (see 
Chapter 3 Materials and Methods). For antagonist mode assays, compounds were diluted 
in PBS in the presence of 100 µM forskolin and 0.2 µM sodium metabisulfite, and an 
EC80 of DA. Data for antagonist mode assays were collected as relative luminescence 
units (RLUs), and values were normalized to a percentage of max sulpiride inhibition.  
 
-Arrestin-2 recruitment assay – Assays were conducted, with minor modifications, as 
previously published by our laboratory (see Chapter 3 Materials and Methods). 
Compounds were diluted in PBS in the presence of 0.2 µM sodium metabisulfite and an 
EC80 of DA for antagonist mode assays. Data were collected as RLUs and subsequently 




Primary glia and striatal neuron culture – Isolation and culturing of cells was conducted 
as described previously209,210. Glia Cultures: Briefly, dissection buffer consisting of 
ACSF (119 mM NaCl, 5 mM KCl, 1 mM MgCl2, 30 mM dextrose, 25 mM HEPES, pH 
7.4, without Ca2+) and glia media (DMEM supplemented with 10% FBS, 10 units/ml 
penicillin, 10 g/ml streptomycin, and Glutamax) were prepared and stored at 4°C until 
use. Embryonic or neonatal mice were euthanized by rapid decapitation. Cerebral 
cortexes were dissected, and digested in papain solution (100 ml papain and 20 l 1% 
DNase I in 2 ml dissection buffer) at 37°C for 20 min. Following digestion, tissue was 
rinsed with 10 ml pre-warmed glia media, triturated with a fire-polished glass Pasteur 
pipette, diluted in glia media and filtered through a 70 m cell-strainer. Cells were then 
seeded into collagen coated T75 flasks (2-3 embryos/flask) and placed into a 37°C cell 
culture incubator overnight, fed the next day and dissociated with 0.05% trypsin when 
nearing confluence in 10-12 days. Glia were cultured directly onto collagen coated inserts 
(Millipore PICM03050) placed in 6 well plates (one confluent T75 flask per 6-well plate/ 
2 ml/insert) and used for conditioning neuronal cultures. Neuronal Cultures: Pregnant 
mice (E15-18) were euthanized with CO2, and embryonic mice were euthanized by 
decapitation. The striatum was dissected from the brain tissue and placed into a 15 ml 
conical tube with ice-cold dissection buffer, for culture of MSNs. Tissues are dissociated 
with papain as described above and counted. Neurons were then seeded on poly-L-Lysine 
coated glass coverslips previously incubated in a 37°C incubator overnight in plating 
media (Neurobasal supplemented with 5% heat-inactivated horse serum, 10 units/ml 
penicillin, 10 g/ml streptomycin, Glutamax; 2% B27 supplement) at a density of 0.4 × 
106 cells per well of a 6-well plate, and cultured in a 37°C incubator overnight (neurons 
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are DIV 0). The next day (DIV 1), coverslips containing neurons were placed underneath 
the glia culture inserts, one coverslip/well. For transfection of primary striatal neurons, 
each neuronal culture/coverslip was transfected with 1 g of D2R-pHluorin DNA 
construct211 using 2 l of Lipofectamine 2000 (Invitrogen, Calrlsbad, CA) according to 
the manufacturers recommendation. Briefly, Lipofectamine 2000 reagent and DNA 
construct were diluted in supplement free Neurobasal medium, incubated for 20 min at 
room temperature. Glia culture inserts were removed momentarily from the 6-well plates 
and 200 l Lipofectamine/DNA mixture was added to each coverslip, followed by return 
of the glia culture inserts to each well. Neurons were incubated with the 
Lipofectamine/DNA mixture at 37°C for 2-4 h. After the 2-4 h incubation period, glia 
inserts were removed again and the media containing the Lipofectamine/DNA mixture 
was removed, glia culture inserts were returned to each well, and the glia media from 
each insert was changed. Neurons were cultured for an additional 24-72 h prior to 
imaging. 
 
D2R immunocytochemistry – MSNs were transfected with pH-DRD2 for 48 h as 
described above211, washed with ACSF, and incubated with rabbit polyclonal anti-GFP 
antibody (1:200 dilution; a gift from Dr. Richard L. Huganir, Department of 
Neuroscience, Johns Hopkins University School of Medicine/HHMI) for 1 h at 4°C to 
stain surface receptors. Neurons were subsequently fixed with Parafix (4% sucrose, 4% 
paraformaldehyde in PBS, pH 7.4), permeabilized with 0.25% Triton X-100 in PBS, 
blocked with 10% normal donkey serum in PBS at 37°C for 1 h, and subsequently 
stained with a mouse monoclonal GFP antibody at a dilution of 1:100 (a gift from Dr. 
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Richard L. Huganir) to stain for total pH-DRD2 to amplify green fluorescent signal from 
superecliptic pHluorin at neutral pH. Neurons were then washed four times and 
subsequently stained with Alexa Fluor 647 Red-X donkey anti-Rabbit IgG (H+L; 1:100 
dilution; CAT 647 711-605-152, Jackson Immunoresearch Laboratories, Inc.) and Alexa 
Fluor 488 donkey anti-mouse IgG (H+L; 1:200 dilution; CAT 705-545-147, Jackson 
Immunoresearch Laboratories, Inc.) secondary antibodies. Images were acquired on an 
inverted Zeiss fluorescent microscope using a 40× objective (NA, 1.30) and a 2.5× relay 
lens between the microscope and the camera. Fluorescent intensities were quantified 
using ImageJ (NIH, http://rsb.info.nih.gov.ezproxy.welch.jhmi.edu/ij/). The ratio between 
surface to total of pH-DRD2 signal was normalized to the control group (pH-DRD2 
without DA stimulation). 
 
Total Internal Reflection Fluorescence Microscopy – Total internal reflection 
fluorescence (TIRF) imaging was conducted on a custom made in house system with a 
100-mW Cyan laser for excitation, and an Electron Multiplying Charge Coupled Device 
(EMCCD) camera for a detector. Prior to imaging experiments, a coverslip containing 
transfected neurons as described above was assembled into a live-imaging chamber and 
incubated with ACSF. Transfected neurons were identified visually under epifluorescent 
imaging, and subject to a 1 min photo-bleach to eliminate pre-existing pHluorin 
fluorescence on the plasma membrane. Following photobleaching, recording is 
performed for 1 min at 10 Hz with each recording containing 600 images and the gain 
setting of the electron multiplier set to maximum. Individual insertion events are 




Biotinylated D2R internalization assay – HEK293 cells were transfected with HA-D2R. 
72 h after transfection, cell surface proteins were labeled with Sulfo-NHS-SS-Biotin (30 
min on ice). After washes, cells returned to incubator with different treatments for 30 
min. Cells were then incubated with MESNA to cleave biotin from surface proteins. Cell 
lysate was incubated with avidin beads to precipitate biotin labeled (internalized) 
proteins. Western blotting was then used to detect internalized D2R and TfR with specific 
HA antibody and TfR antibody. The concentrations of quinpirole, 1547, 3-PPP, and 
Aripiprazole are all 10 µM. Western Blot of Anti-HA-D2R, to detect internalized D2R, 
and anti-TfR was used as loading control. Densitometric analysis of internalized 
D2R/TfR. One-way ANOVA test, * P<0.05; ** P<0.01.  
 
BRET biosensor-based D2R internalization assay – The receptor internalization 
biosensor was constructed using a modified GFP10. They were synthesized at 
GeneScript® (Piscataway, NJ) and subcloned into pcDNA 3.1/zeo(-) using infusion 
technology (Clontech, CA). For assays HEK293SL cells were cultured in DMEM 
supplemented with 5% fetal bovine serum and 20 g/ml gentamycin and maintained at 
37°C in 5% CO2 and 90% humidity. Cells were seeded at 7.5×10
5 cells per 100 mm dish 
a day before transfection and transfected using calcium phosphate as previously 
described. After 18 h of transfection, the medium was replaced, and the cells were re-
plated onto poly-ornithine coated white 96-well plates (~25,000 cells per well). The next 
day, cells were washed once with pre-warmed Tyrode’s buffer (140 mM NaCl, 2.7 mM 
KCl, 1 mM CaCl2, 12 mM NaHCO3, 5.6 mM D-glucose, 0.5 mM MgCl2, 0.37 mM 
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NaH2PO4, 25 mM HEPES, pH 7.4), and then stimulated with various concentrations of 
ligands in Tyrode’s buffer for 30 min at 37 °C. The cell-permeable substrate, 
coelenterazine 400a was added at a final concentration of 5 µM in Tyrode’s buffer 3~4 
min before BRET measurements. Measurements were performed by using Synergy2 
(BioTek®) microplate reader with a filter set of 410 ± 80 nm and 515 ± 30 nm for 
detecting the Rluc8 renilla luciferase (donor) and GFP10 (acceptor) light emissions, 
respectively. The BRET signal was determined by calculating the ratio of the light 
intensity emitted by the GFP10 over the light intensity emitted by the Rluc8 and 





D2R internalization is weakly stimulated by MLS1547 
MLS1547 has been shown to act as a biased D2R agonist, displaying high 
efficacy at stimulating G protein linked signaling, but failing to recruit β-arrestin-2 as 
observed using several in vitro assays212. As previously discussed, one advantage of a 
compound biased in this manner is that in theory it would have the ability to activate G 
protein signal in neurons without causing rapid desensitization/tolerance usually 
associated with arrestin recruitment by non-biased agonists. This led us to delve further 
into MLS1547 signaling bias by examining agonist-mediated D2R internalization. As it is 
thought that most agonist-induced D2R internalization is mediated by β-arrestin-2200 we 
predicted that MLS1547 would have a diminished ability to stimulate receptor 
internalization when compared to a non-biased agonist.  
In a first approach, we used a BRET-based biosensor in transiently transfected 
HEK293 cells that employs a modified GFP protein that is cell surface-localized213. Co-
transfection of D2R-Rluc8 and the cell surface-localized GFP protein results in 
constitutive BRET when they are expressed at the cell surface and in close proximity. 
Upon agonist stimulation the receptor is internalized but the GFP protein remains in the 
plasma membrane resulting in a decrease in the BRET ratio due to separation of the 
BRET donor (D2SR-Rluc8) and acceptor (GFP). As shown in Figure 27A, stimulation 
with DA resulted in a dose dependent decrease in the BRET ratio with an EC50=0.14 μM 
± 0.04. When cells are stimulated with MLS1547 they failed to elicit a significant change 
in BRET ratio at concentrations up to 30 μM, a concentration that results in full 
activation of G protein signaling (cf. Figure 22 and Figure 23). Figure 27B demonstrates 
single concentration data using 10 μM of DA or 30 μM of MLS1547, where DA 
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treatment resulted in significant receptor internalization when compared to the untreated 
control, whereas MLS1547 treatment did not result in any significant change in BRET. 
These initial findings suggest that MLS1547 does not promote D2R internalization. 
 
We next took a different approach to assess agonist-induced internalization using 
a cell surface biotinylation assay and transient expression of HA-tagged D2R in HEK293 
cells. In this type of experiment, the D2R is labeled with biotin at the cell surface 
followed by agonist treatment of the cells. Biotin is then cleaved from cell surface 
 
Figure 27: Investigation of D2R internalization in non-neuronal cell systems.  
 A: HEK293 cells were transiently transfected with D2R-Rluc8 and a modified GFP10, which together 
produce constitutive BRET. On the day of assay, the cells were stimulated with either dopamine (DA) 
or MLS1547 for 30 min at 37oC before BRET measurement. The data are graphed as mean dose-
response curves from three experiments. DA exhibited an EC50 of 0.14 ± 0.04 mM for BRET 
reduction/D2R internalization, while MLS1547 treatment failed to alter the BRET signal. B: Maximum 
BRET signal obtained after treatment with vehicle (control, 0.81 ± 0.02), 10 μM DA (0.65 ± 0.02), or 
30 μM MLS1547 (0.79 ± 0.03). All data are expressed as mean ± SEM of the BRET ratio from three 
independent experiments. *P<0.05, unpaired Student’s t-test compared to untreated controls. C: HA-
tagged D2R was transiently transfected into HEK293 cells and surface D2R was biotinylated as 
described in Methods. After washing, cells were treated with either vehicle (control), 10 μM quinpirole, 
or 30 μM MLS1547 or for 30 min at 37oC. Biotin was cleaved from D2R that remained on the cell 
surface, followed by cell lysis and isolation of biotinylated (internalized) D2R using avidin beads. 
Western blotting was used to detect D2R and also transferrin receptor (TfR) (as a gel loading control). 
A single experiment, representative of three, is shown. D: Densitometric analyses were performed and 
the data expressed as D2R/TfR ratios, relative to the untreated controls (1.0). Treatment values are 
provided as mean ± S.E.M: quinpirole = 2.8 ± 0.2 and MLS1547 = 1.5 ± 0.03. One-way ANOVA 




proteins and internalized receptors (that are protected from cleavage) are isolated via 
binding to avidin beads214. Figure 27C shows a Western blot of internalized D2R protein 
after treatment with 10 μM of MLS1547 or 10 μM of the D2R agonist quinpirole. The 
D2R is visualized using an antibody directed to an HA tag on the receptor (top blot). 
Visualization of the transferrin receptor (TfR) was also performed as a gel loading 
control (bottom blot). The blots were quantified using densitometric analysis and graphed 
as a percentage of D2R protein divided by the loading control (TfR), with untreated 
control levels being set to 1 (Figure 27D). Notably, treatment with the D2R agonist 
quinpirole resulted in a robust loss of cell surface D2R protein following treatment 
(Figure 27D), but MLS1547 treatment also resulted in statistically significant receptor 
internalization. However, this response was only a fraction of that produced by quinpirole 
(Figure 27D). Thus these results differed somewhat from those obtained using the BRET 
assay in that MLS1547 promoted a small degree of receptor internalization. 
As the above experiments used non-neuronal cells (HEK293) to examine D2R 
internalization, we wished to examine this response within a neuronal context. Thus, we 
performed studies to examine D2R internalization and recycling in striatal neurons from 
E15-E18 mouse embryos using both immunocytochemistry (ICC) and TIRF 
microscopy209–211. Figure 28A shows quantification of ICC assays following a 45 min 
incubation with 10 μM DA, 30 μM MLS1547, 30 μM sulpiride, or no compound 
(control). Data are expressed as the ratio of surface to total receptors normalized to the 
control. Sulpiride was used as a negative control, and as expected, no significant D2R 
internalization was detected after sulpiride treatment (surface:total=1.05 ± 0.08). DA 
treatment resulted in a significant decrease in relative D2R surface expression when 
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compared to the control (DA surface:total = 0.72 ± 0.02, control surface:total=1.00 ± 
0.02, p <0.0001). Notably, MLS1547 caused a statistically significant degree of receptor 
internalization when compared to the control (MLS1547 surface:total = 0.90 ± 0.03, 
p<0.0262). However this response was much less than that observed with DA 
(p<0.0001). 
 
For TIRF microscopy studies, the same neurons used in the ICC studies were used 
to look at vesicle reinsertion. As described in the Materials and Methods209,211, cells were 
transfected with a D2R construct tagged with a pH dependent GFP (pHluorin) that loses 
fluorescence in the acidic environment of vesicles. This enables the visualization of 
vesicle exocytosis or “reinsertion”, as pHluorin fluorescence is regained the moment the 
vesicle fuses with the cell membrane. It has been shown that an increase in measured 
 
Figure 28: Investigation of D2R internalization in neuronal cell systems. 
A: Medium spiny neurons were prepared and transfected with the D2R-pHluorin construct (pH-DRD2) 
as described in Methods. 48 hr later, the neurons were treated with vehicle (control) or 10 μM 
dopamine (DA), 30 μM MLS1547, or 30 μM sulpiride for 45 min. Neurons were washed and then 
stained with a polyclonal GFP antibody to detect surface D2R followed by fixation, permeabiization 
and re-staining with a monoclonal GFP antibody to detect total cellular D2R. The ratios between 
surface to total pH-DRD2 signal were normalized to the control group in each experiment and are 
expressed as mean ± S.E.M of the indicated number of cells (n): control = 1.00 ± 0.02, n = 746; DA = 
0.72 ± 0.02, n = 627; MLS1547 = 0.90 ± 0.03, n = 812, sulpiride = 1.05 ± 0.08, n = 171. One-way 
ANOVA followed by Bonferroni’s post-test was performed: *p<0.0001 and **p<0.0262. B: Medium 
spiny neurons expressing the D2R-pHluorin construct were exposed to vehicle (control) or 10 μM DA, 
30 μM MLS1547, or 30 μM sulpiride for 20 min and the number of reinsertion events/(min×μm2) were 
visualized in real time as described in Methods. The average reinsertion frequencies for the drug 
treatments were normalized to the control group in each experiment and are expressed as mean ± S.E.M 
of the indicated number of cells (n): control = 1.00 ± 0.20, n = 51; DA = 5.70 ± 0.54, n = 49; MLS1547 
= 1.73 ± 0.22, n = 50, sulpiride = 1.56 ± 0.34, n = 15. One-way ANOVA followed by Bonferroni’s 
post-test was performed, *p<0.0001. 
88 
 
receptor internalization correlates to an increase in reinsertion frequency, which is 
theorized to be due to recycling of D2Rs back to the cell membrane following agonist-
stimulated endocytosis210,211. The frequency of D2R-containing vesicle reinsertion is 
measured via real-time TIRF microscopy by photobleaching a neuron and then treating 
cells for 20 min with 10 μM DA, 30 μM MLS1547, 30 μM sulpiride, or no treatment 
(control). Vesicle re-insertions to the membrane were counted for 5 min, and displayed as 
the number of reinsertions per minute per μm2 cell surface membrane (Figure 28B). DA 
treatment caused a significant increase in re-insertion frequency when compared to the 
control (DA frequency=5.70 ± 0.54, control frequency=1.00 ± 0.20, p < 0.0001), 
correlating to an increase in receptor internalization. MLS1547 treatment in resulted in a 
small but statistically non-significant increase in reinsertion frequency (frequency=1.73 ± 
0.22) when compared to the control.  
Taken together, our data show that MLS1547 promotes little (biotinylation and 
ICC assays) to no (BRET and TIRF assays) D2R internalization, confirming the notion 
that it is a highly G protein biased agonist. The small degree of internalization seen in the 
biotinylation and ICC assays may suggest that MLS1547 is incompletely biased, that is, it 
has a low efficacy for recruiting β-arrestin-2 that was not observed directly in the arrestin 
recruitment assays. Alternatively, D2R internalization may not be solely dependent on 
arrestin, and MLS1547 may be promoting receptor internalization via a non-arrestin-




MLS1547 analog structure-activity relationships 
As our goal is to develop an in vivo probe for G protein-mediated D2R signaling, 
we engaged in further chemical optimization. Previously, we obtained 22 MLS1547 
analogs and tested them in functional assays for cAMP accumulation and β-arrestin-2 
recruitment. In order to better understand the importance of various functional groups, as 
well as to strive for a more potent and more selective compound, a structured iterative 
chemical synthesis of 46 additional analogs of MLS1547 was conducted. Figure 29A 
illustrates the parental compound and the previously developed pharmacophore model 
highlighting four regions of the molecule that are believed to be important for G protein 
bias. These include a hydrophobic binding moiety (green ball), two aromatic groups 
(orange balls), and a positively charged feature (pink ball). Keeping this in mind, Figure 
29B shows the four main areas of the molecule that we selected for derivation to develop 
a more detailed SAR in this series of compounds. 
 
 
Figure 29: Structure of parent compound, MLS1547.  
A: Pharmacophore model depicting four required features for agonist activity and G protein bias. Green 
represents a hydrophobic component, orange represents the two aromatic components, and purple 
represents a positively charged component. B: The four main areas of the scaffold that were modified 
are indicated.  
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SAR: a hydrophobic binding moiety is necessary for G protein bias 
We have previously postulated that a hydrophobic binding pocket comprised of 
D2R residues I184, F189, and V190 was involved in G protein biased signaling (Figure 
26)212. The chloro group (Figure 29B, area 1) on MLS1547 was postulated to interact 
with this pocket and prevent the tilting of TM5 during receptor activation. With this in 
mind, our first approach was to further investigate the influence of this hydrophobic 
binding moiety on compound bias by constructing multiple analogs of MLS1547 that 
vary in this part of the molecule. Table 5 and Table 6 show analogs that were designed to 
address the importance of the hydrophobic binding moiety (Figure 29B, area 1) in 
maintaining compound bias.  
In Table 5, it can be seen that removing the chloro group in area 1 (NCGC2-5) 
caused a gain in arrestin agonist activity (loss of signaling bias), whereas replacing the 
chloro group with a bromo group such as with KU2-1, caused a decrease in G protein 
agonist potency (EC50 from 260 nM to 8 M) and efficacy. Similar ClH substitutions 
within the context of related MLS1547 derivatives (KU2-4, KU2-6, KU2-7, KU2-8) 
support the need for the hydrophobic moiety in order for the compound to exhibit strong 
G protein signaling bias. 
We previously found that a naphthalene group can provide the necessary 
hydrophobic feature for G protein bias, but only if oriented correctly such that it can 
engage the hydrophobic pocket in the D2R (Figure 26D)212. For instance, NCGC1-D03 is 
highly G protein biased whereas NCGC2-6 is not (Table 6). Other analog pairs following 
this change in naphthalene orientation exhibited similar phenomena. Interestingly, 
compounds with indole groups substituted for the naphthalene group (KU7-1 and KU7-
6), yet in a similar orientation as the non-biased NCGC2-6 compound, also exhibited 
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non-biased signaling activity (Table 6). In aggregate, these data confirm and strengthen 
our previously proposed pharmacophore model for G protein signaling bias of the 
MLS1547 scaffold. Thus a hydrophobic moiety is integral to G protein biased signaling 
activity at the D2R, and this moiety can be provided either through a halogen group or a 





Table 5: Removing a hydrophobic moiety by changing chloro group on ring B causes a loss in G protein bias. 
 





Table 6: Removing a hydrophobic moiety by moving linker location on ring B causes a loss in G protein bias. 
 





SAR: the hydroxyl group enhances G protein and arrestin agonist activity 
We next examined the importance of the hydroxyl group (Figure 29B, area 2) 
attached to ring B by constructing analogs seen in Table 7. Other analog sets in Table 7 
show that replacing the hydroxyl group with either a chloro (KU3-2, KU3-3, or KU3-4, 
KU2-4), methyl (KU4-3, KU4-4, KU4-5 or KU2-7), or methoxy (KU2-3, KU2-2) group 
generally results in a complete loss, or diminishment, of agonist activity. Notably, we 
observed that the two methoxy derivatives (KU2-2 and KU2-3) functioned as antagonists 
of both D2R signaling assays suggesting that, while they lost agonist efficacy, they 
retained affinity for the receptor. In contrast, the chloro and methyl derivatives were 
ineffective as antagonists and lost all functional activity at the D2R. These data suggest 
that the hydroxyl group on ring B is a strong driver of both affinity and efficacy in this 





Table 7: Changing the hydroxyl group on ring B to a less polar functional group causes loss in G protein and arrestin agonist activity. 
 





SAR: a carbonyl group on the linker region causes complete loss in D2R activation 
We next investigated the importance of the linker between rings B and C of the 
scaffold (Figure 29B, area 3) by converting the methylene group to a carbonyl group 
(Table 8). While each of the parent scaffolds (KU7-6, KU8-1, KU7-1 and KU8-2) were 
relatively unbiased agonists, the creation of a carbonyl linker resulted in a complete loss 
of agonist activity for the resulting compounds (KU7-14, KU7-15, KU7-7 and KU7-8). 
There are two likely explanations for these results. First, the creation of an amide bond 
will lower the pKa of the proximal nitrogen group such that is not protonated at 
physiological pH. This will result in the loss of the positively charged feature in the 
MLS1547 pharmacophore model (Figure 29A). Secondly, the introduction of a carbonyl 
group removes flexibility between the A/B and C/D ring groupings, which likely has 





Table 8: Adding a carbonyl group to linker causes loss in G protein and arrestin activity. 
 





SAR: aromaticity of ring D and nitrogen placement around ring D are integral to G 
protein and arrestin agonist activity 
Based on previously published SAR and the pharmacophore model, the pyridine 
moiety of MLS1547 (Figure 29B, area 4) is believed to confer increased agonist potency, 
likely through formation of a hydrogen bond to T412 of the D2R. To further dissect the 
influence of the pyridine ring, we initially replaced it with a non-aromatic cyclohexane 
group within the context of both G protein biased and non-biased scaffolds (Table 9). 
Notably, each of these analogs lost all agonist activity at both G protein- and arrestin-
mediated signaling. These data indicate that the aromaticity of ring D is essential for 
agonist activity. All of the compounds with the cyclohexane substituents did retain 
affinity for the D2R as evidenced by their ability to antagonize both G protein and 
arrestin recruitment activities. Further, as illustrated in Table 10, the addition of a bulky 
functional group to ring D in the para position relative to the piperazine ring resulted in a 
complete loss of all activity (see MLS1547 vs. KU4-2, and KU1-6 vs. KU4-1 or KU3-
12). This highlights the importance of ring D for compound activity and suggests that 





Table 9: Changing ring D from an aromatic group to non-aromatic cyclohexane causes loss in G protein and arrestin agonist activity. 
 
Yellow compounds are previously reported in Chapter 3. Red compounds appear in multiple tables. 
 
Table 10: Adding a bulky functional group para to the linker on ring D causes loss in G protein and arrestin agonist activity. 
 





To further investigate the role of the pyridine moiety in MLS1547 activity, we 
modified the location of the nitrogen atom within the ring. Firstly, Table 11 shows that 
removing the nitrogen altogether reduces agonist efficacy, as previously reported212. 
Further, moving the nitrogen to the meta position (Table 11) results in a complete loss of 
activity within the context of MLS1547 (see KU3-6 and KU3-5) as well as the active 
analogs KU7-1 and KU7-6 (see KU7-4 and KU8-3). Similarly, moving the nitrogen to 
the para position (Table 11) is not tolerated and results in a complete loss of activity 
within the context of several active scaffolds (see MLS1547, KU7-1, and KU2-7 vs. 
KU3-5, KU7-2 and KU3-11). These latter results correlate with those obtained with 
analogs containing substitutions at the para position on ring D (Table 5), which were 
likewise not tolerated. Overall, these data illustrate the importance of a nitrogen at the 
ortho position of ring D in order for the compound to exert agonist activity at the D2R.  
We were next interested in examining the effects of adding a second nitrogen to 
ring D while maintaining the presence of a nitrogen at the ortho position (Table 12, Table 
13, and Table 14). Initially, a second nitrogen was added at the second ortho (Table 12) 
position within the context of highly (MLS1547) or moderately (KU2-4 and KU2-7) G 
protein biased, or non-biased (KU7-1 and KU7-6) agonists. In general, this substitution 
was well tolerated with respect to G protein-mediated signaling. In fact, the potencies for 
agonist activity increased in all cases. Additionally, for compounds with a benzene for 
ring B (MLS1547, KU2-4, and KU2-7), no significant change in G protein agonist 
efficacy was seen when ring D was changed (KU 1-1, KU2-6, and KU2-8). However, in 
compounds with a pyrrole for ring B (KU7-1 and KU7-6), adding a second ortho nitrogen 
to ring D caused a decrease in G protein agonist efficacy (see KU7-1 vs. KU8-1). 
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Notably, in most cases there was also an increase in arrestin-mediated recruitment (see 
KU1-1, KU2-6, KU2-8), although this was not seen when the parent compound was 
unbiased (see KU8-1, KU8-2). Thus, addition of a second ortho nitrogen in ring D 
generally resulted in loss of G protein bias when compared to compounds with a single 
ortho nitrogen, although the dual ortho nitrogen containing compounds did retain agonist 
activity at the D2R.  
The effects of adding a second nitrogen at the meta position of ring D in the 
presence of a nitrogen at the ortho position was next investigated (Table 13). Within the 
context of the parent MLS1547 scaffold, this substitution was well tolerated (KU1-6) and 
G protein bias was maintained, albeit with a slight decrease in G protein-mediated 
signaling efficacy. Interestingly, within the context of the partial, but G protein biased 
agonist KU2-3, the addition of a meta nitrogen resulted in an increase in G protein 
signaling efficacy (KU2-2). Markedly, in these cases, both of the parent scaffolds contain 
a chloro group in area 1 (Figure 29A). In contrast, within the context of the less biased 
KU2-7 scaffold lacking a chloro group in area 1, the addition of a meta nitrogen resulted 
in a complete loss of activity (KU3-9).  
Finally, we investigated the addition of a second nitrogen at the para position of 
ring D in the presence of a nitrogen at the ortho position (Table 14). In all cases (KU3-13, 
KU7-5 and KU8-4), this resulted in a complete loss of activity for both G protein- and 
arrestin-mediated D2R signaling. This finding is consistent with the results observed 
when the single nitrogen on the pyridine is moved from the ortho to para position (Table 
11) or the addition of a bulky functional group at the para position (Table 10). These data 
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support the need for a single nitrogen ortho to the linker without any substitution at the 
para position to maintain the activity and bias of the parent compound.  
Generally it has been observed that although the addition of a second ortho 
nitrogen increases potency, it also results in a less biased compound. Overall adding a 
second nitrogen ortho or meta to the linker causes somewhat scaffold-dependent effects, 
whereas a second nitrogen para to the linker causes a loss of agonist activity. 
Consequently, it seems that overall nitrogen number and location is an essentially 







Table 11: Removing the nitrogen from ring D or moving the ortho nitrogen to the meta/para position relative to the linker causes loss in G protein and 
arrestin activity. 
 




Table 12: Adding a second nitrogen ortho to the linker causes a gain in G protein agonist potency and arrestin agonist efficacy. 
 





Table 13: Adding a second nitrogen meta to the linker causes decreased G protein activation potency, and scaffold dependent effects on G protein 
activation efficacy. 
 
Yellow compounds are previously reported in Chapter 3. Red compounds appear in multiple tables. 
 
 
Table 14: Adding a second nitrogen para to the linker causes loss in G protein and arrestin agonist activity. 
 






In Chapter 3, the first identification of a G protein biased agonist, MLS1547, for 
the D2R was reported. Here, additional aspects were investigated with respect to 
MLS1547 SAR and G protein biased signaling. First, it was investigated whether or not 
MLS1547 would stimulate D2R internalization, which is believed to be dependent on β-
arrestin-2 recruitment to the D2R27,200. The data generated from experiments performed 
in both non-native cells and MSNs indicated that MLS1547 is a strongly biased 
compound that stimulated only a very low degree of arrestin recruitment to the D2R 
(Figure 27 and Figure 28). It is possible that the discrepancy between the functional 
arrestin-recruitment assays, which report no arrestin recruitment to the D2R (Figure 23), 
and the internalization assays, which report D2R internalization (Figure 27 and Figure 
28) is due to a combination of factors involving experimental design and/or cellular 
context. 
The differences between β-arrestin-2 recruitment and internalization data may 
also be due to differences in assay sensitivity. This is supported by the different results 
seen in the ICC vs. TIRF data, which share the exact same batches of cells harvested and 
transfected on the same days, and differ only in the technique applied to detect receptor 
internalization. In the ICC data, MLS1547 stimulates a low, but statistically significant 
amount of D2R internalization when compared to the control (Figure 28A). However, 
while the TIRF microscopy method showed a trend towards an elevated level of 
MLS1547-stimulated D2R internalization, it was not statistically significant (Figure 
28B). These results suggest that MLS1547 may stimulate a low degree of β-arrestin-2 
recruitment that was not measurable in the direct assays utilized which results in a low 
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amount of receptor internalization with prolonged treatment. In this scenario, the 
conclusion would be that MLS1547 is highly, but incompletely biased for G protein 
signaling. Alternatively, the small amount of MLS1547-induced D2R internalization may 
be occurring through an arrestin-independent mechanism. There is precedent for this in 
other receptor systems where arrestin-independent internalization has been observed215.  
Although MLS1547 stimulates a low degree of D2R internalization, this does not 
mean that a D2R internalization deficient agonist cannot be found. It has been 
demonstrated that G protein activation can function independently from arrestin 
recruitment when the D2R is activated. One study found that mutating four D2R residues 
(I212A+Y213A+I214A+V215A) in the third ICL caused the receptor to activate G 
protein signaling without causing arrestin-mediated D2R internalization when treated 
with a non-biased agonist204,216. Another study showed that a different set of mutations 
within the 3rd TM domain caused either G protein biased (L125N+Y133L) or arrestin 
biased (A135R+M140D) signaling when the D2R was stimulated with a non-biased 
agonist205. Our molecular modeling (Figure 26) adds to this body of work, showing that 
when interacting with a ligand, three residues in the 2nd extracellular loop (I184) and the 
5th TM domain (F189, V190) may confer bias for G protein signaling212. Interestingly, 
mutating the D2LR at F189Y conferred D4R-like affinities to the mutated D2R for D4R 
ligands, indicating that this might be an important residue for receptor function217. 
Coincidentally, MLS1547 has the highest affinity for D4R, followed by D2R, then D3R 
(Figure 24 and Figure 25). 
Because MLS1547 stimulated a small degree of D2R internalization, we sought to 
optimize the compound by increasing G protein activation potency while maintaining a 
108 
 
lack of detectable arrestin recruitment, and hopefully create a D2R compound that is 
internalization deficient. Such a compound might represent a lead for a therapeutic drug 
(for instance, in treating Parkinson’s disease) as it might elicit prolonged stimulation of 
the D2R due to a lack of receptor desensitization/internalization. In addition, we wanted 
to build upon and refine the pharmacophore model by generating additional SAR.  
Previously, we obtained 22 MLS1547 analogs and tested them in D2R functional 
assays for cAMP accumulation and β-arrestin-2 recruitment (see Chapter 3)212. These 
original analogs were chosen based on commercial availability and none showed 
improved G protein activation potency while maintaining bias. These data did, however, 
help us to devise a molecular model for how G protein biased signaling of the D2R can 
occur (Figure 26). Using this model, 46 additional MLS1547 analogs were synthesized. 
While a compound with improved potency at G protein signaling was not found, these 
compounds enabled the development of additional SAR which both reinforced and 
refined the existing model for G protein biased D2R agonist binding.  
Most of the SAR confirmed the importance of molecular signatures proposed to 
be essential for G protein bias, such as a hydrophobic binding moiety and the aromaticity 
at ring D as well as the placement of the nitrogens around that ring. Beyond that, two new 
chemical characteristics were proposed to be important for G protein bias D2R activation: 
the hydroxyl group on ring B (Table 7; Figure 29, area 2) and the linker region between 
rings B and C (Table 8; Figure 29, area 3). These areas open the door for a better 
understanding of ligand binding to the D2R, and will enable us to identify residues that 




Chapter 5: D2R β-arrestin-2 biased Ligands Screen 
Background 
 As described in the introduction sections of Chapters 3 and 4, there may be utility 
for either G protein or arrestin biased ligands. Chapters 3 and 4 outlined the results of a G 
protein biased agonist screen, of which there were no preceding examples for the D2R. 
However, there was precedent for low efficacy arrestin biased D2R agonists165,166, 
indicating that more potent and efficacious arrestin biased D2R ligands may exist.  
In addition to functional selectivity, targeting allosteric receptor sites is a novel 
way to narrow the signaling capabilities of a ligand. Allosteric ligands can affect the 
receptor in one of three ways (Figure 30): altering the affinity of an orthosteric binding 
ligand, altering the efficacy of an orthosteric binding ligand, or independently stimulating 
or inhibiting receptor signaling. It is important to note that by definition, a functionally 
selective antagonist must be allosteric, as it would inhibit one pathway while allowing the 
activation of other parallel pathways. Because allosteric binding sites are separate from 
the orthosteric binding site, where residues are more highly conserved, an allosteric 
ligand is more likely to interact with residues that are divergent between receptors of the 
same class and/or family. As a result, an allosteric and functionally selective D2R ligand 




Allosteric binding sites have already been identified for the D2R218, and 
theoretically, there is almost unlimited potential for the identification of other allosteric 
sites219–221. With the therapeutic and investigative value of a functionally 
selective/allosteric D2R ligand in mind, a screen to detect arrestin biased D2R agonists, 
antagonists, and potentiators was performed by our lab.  
  
 
Figure 30: Allosteric modulation of GPCRs. 
Allosteric compounds either directly alter downstream signaling (green line) or alter the affinity (red 




Materials and Methods 





The arrestin biased D2R ligand screen was performed using the same compound 
library and functional assays used in the G protein biased D2R ligand screen (Chapter 3). 
The key difference was in the way the screen was performed (cf. Figure 20 and Figure 
31). This assay was performed twice, once using an EC20 concentration of DA to detect 
potentiators, and once using an EC80 concentration of DA to detect potential antagonists. 
Each screen employed a two-add, two-read protocol (Figure 32) applied to the 
DiscoveRx D2R-β-arrestin-2 assay. First the library compound was added, followed by a 
detector read, then an EC20/80 concentration of DA was added, followed by a second 
detector read. Consequently, three assay scenarios resulted in a three pools of “hits”:  
1. Agonists (either allosteric or orthosteric): the library compound exhibited agonist 
activity in the first read, producing a signal. 
2. Potentiators (allosteric): the compound potentiated the signal stimulated by an 
EC20 concentration of DA. 
3. Antagonists (allosteric): the compound inhibited the signal stimulated by an EC80 





Compounds were selected from each pool of hits, based on their potency, 
efficacy, and chemical diversity, and were subjected to various secondary counterscreens 
(Figure 31), similar to the G protein biased agonist screen. 1,341 agonists, 1,325 
 
Figure 32: Compound add steps for arrestin biased D2R screens. 
This schematic depicts the screening paradigm for detecting agonists (first compound add, both red and 
purple lines), antagonists (red line, second add), and potentiators (purple line, second add). 
 
Figure 31: Flowchart of the D2R arrestin biased screen protocol. 
Abbreviations: CRC (concentration response curve), HTS (high-throughput screen), PTGER2 




potentiators, and 2,237 antagonist hits were detected in the primary screen. For the 
antagonists, an additional prostaglandin counter screen was performed to weed out 
compounds that inhibited the β-galactosidase enzyme integral to the arrestin assay instead 
of the receptor itself. Twelve antagonists passed the prostaglandin counter screen, and 6 
were sent to us by our collaborators at NCATS. The other 6 antagonists were unavailable 
commercially, and were dropped from the validation step. None of the potentiators or 
antagonists were validated in our lab as biased compounds. However, one agonist, 
dihydroergocornine showed arrestin biased signaling (Figure 33). Unfortunately, a pure 
formulation of this compound was not available commercially and it was not cost 




Figure 33: Comparison of cAMP and arrestin assay data for β-arrestin-2 biased D2R agonist.  
Compounds were tested as agonists in the arrestin recruitment and cAMP accumulation DiscoveRx 
assays. Dihydroergocornine showed a 100-fold bias towards arrestin recruitment by potency which was 
not seen with the dopamine (DA) control. Data are representative of 3-4 independent experiments and 
plotted as a percentage of the maximum response observed with dopamine (arrestin assay), or as a 
percentage of the maximum inhibition of forskolin response (cAMP assay). Dihydroergocornine cAMP 
Emax = 81.9% ± 12.1, EC50 = 74.1 nM ± 38.7; dihydroergocornine arrestin Emax = 86.3% ± 8.1, EC50 = 
0.8 nM ± 0.7; DA cAMP Emax = 94.8% ± 2.3, EC50 = 24.4 nM ± 12.5; DA arrestin Emax = 100% ± 0, 




 The goal of this screen was to identify allosteric or orthosteric arrestin biased 
ligands targeting the D2R. These compounds could then be used as scaffold for SAR 
interrogation and pharmacological optimization to increase selectivity, potency, and 
stability. However, we were unable to identify any compounds that could move out of the 
screening stage into the optimization/development stage.  
 The preliminary identification of dihydroergocornine as an arrestin biased agonist 
seemed promising (Figure 33). Dihydroergocornine is a member of the ergopeptine 
(a.k.a. ergopeptide) family of compounds. Ergopeptines and ergolines are validated 
agonists of several neurotransmitter receptors including the DARs. In fact, another 
ergopeptine, bromocriptine, is used to treat Parkinson’s disease222,223. Dihydroergo-
cornine is often found in a tripartite mix of ergopeptines (dihydroergocristine, dihydro-
ergocryptine, and dihydroergocornine) called dihydroergotoxine or ergoloid mesylate, 
which is used to treat age-related cognitive impairment and also stroke victims. 
Unfortunately, no sources for pure dihydroergocornine could be found for further testing. 
A dihydroergocornine analog, ergocornine, which differs only by the saturation of a 
double bond was also of interest (Figure 34, red bonds). However, like 
dihydroergocornine, a source for ergocornine could not be found. 
In the hopes that other ergopeptines might exhibit arrestin biased agonism, several 
compounds belonging to the ergopeptine class were tested using the DiscoveRx cAMP 
accumulation and arrestin recruitment assays. They were found to be unbiased D2R 
agonists (see Figure 34 for structures, data not shown). However, a more systematic 





        
 
Figure 34: Non-biased ergopeptines tested in cAMP accumulation and arrestin recruitment 
assays. 
Dihydroergocornine was found to show some D2R arrestin biased agonist activity (Figure 33). 
Ergocornine was a close analogue of dihydroergocornine that differed only in that a single bond became 
a double bond (red bonds), but could not be obtained for testing. Six other ergopeptines were tested in 




Chapter 6: Conclusions and Future Directions 
 The aim of this dissertation was to develop a better understanding of DAR 
function by investigating two aspects of D1R and D2R signaling: synergistic D1R-D2R 
activation of Ca2+ mobilization, and functionally selective signaling of the D2R. Both 
signaling mechanisms take advantage of the conformational fluidity inherent in the DARs 
and other GPCRs to cause selective activation of specific signaling cascades. This idea is 
supported by a body of work that indicates there are many different ways to manipulate 
GPCR protein conformation to modulate signaling224. The B2 bradykinin receptor has 
been shown to respond directly to cell membrane fluidity, changing its conformation and 
consequent signaling capabilities depending on the state of the membrane, independently 
of ligand-mediated modulation225. Using the β2 adrenergic receptor, it was shown that 
different ligands could stimulate slow or fast activation of signaling. The speed of 
receptor activation was thought to be due to the number of intermediate protein 
conformations (a.k.a. sequential binding states) between the inactive and active state, and 
the amount of time spent in each intermediate conformation226. Modeling has supported 
the idea of GPCR conformation plasticity172,227,228, and the change in protein 
conformations has been more directly observed through crystallization of inactive- and 
active-state receptors196,197,229. 
In Chapter 2, the proposed D1R-D2R heteromer was investigated. There is 
evidence for the existence of heteromers involving other GPCRs110, and our studies show 
that it is likely that the D1R and D2R work cooperatively to stimulate the observed Ca2+ 
response, but this cooperativity may not be due to direct interactions between the D1R 
and D2R in a heteromeric complex (Figure 18)42. In fact, one study found that the D1R-
D2R could not cooperatively activate the Gq protein at all
78. Furthermore, a presumed 
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D1R-D2R heteromer selective agonist, SKF83959, actually acted as a D1R-D2R 
antagonist (Figure 12) in our assays and has subsequently been shown to act as a 
homomeric D1R agonist131,208. SKF83959 was also found to bind to a wide variety of 
GPCRs and non-GPCRs such as the σ1 receptor (Table 1)133, calling into question any in 
vivo studies where SKF83959 was used as a selective agonist of the D1R-D2R heteromer. 
It is entirely possible that atypical behavioral effects caused by SKF83959 that were 
previously attributed to activation of D1R-D2R heteromers or D1-like DARs are instead 
due to the activation of non-DAR targets133.  
 In Chapters 3 and 5, a library of small molecules was screened against the D2R to 
detect G protein biased agonists and β-arrestin-2 biased agonists, antagonists, and 
potentiators. The arrestin screen was not successful in generating a biased antagonist or 
potentiator, but it did result in the detection of an arrestin biased agonist, 
dihydroergocornine (Figure 33), a member of the ergot alkaloid family. However, while 
further studies with dihydroergocornine, and its close analog ergocornine, were not 
possible due to cost and availability constraints, other ergopeptines were tested using β-
arrestin-2 recruitment and cAMP accumulation assays (Figure 34). These ergopeptines 
were not found to be biased. However, many other ergot alkaloids (ergolines and 
ergopeptines) exist that might be of interest to test to see if one would serve as an arrestin 
biased agonist scaffold. 
The G protein biased D2R screen was more fruitful and led to the identification 
and further characterization of the G protein biased agonist, MLS1547. A pharmacophore 
model based on preliminary SAR of twenty-two MLS1547 analogs was developed 
(Figure 26) and further refined by the SAR of an additional forty-six analogs in Chapter 
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4. It was confirmed that a hydrophobic binding moiety (Figure 29, Table 5, and Table 6) 
is important for G protein bias. Two additional regions of interest were identified on the 
MLS1547 chemical scaffold that contributed to D2R G protein signaling bias: a hydroxyl 
group (designated area 2 in Figure 29B; Table 7) and the linker between two aromatic 
rings (designated area 3 in Figure 29B; Table 8). Further, it was determined that the 
location of a single nitrogen or the placement of additional of nitrogens to ring D (Figure 
29B) can affect G protein signaling bias and activity (Table 9 - Table 14). This SAR can 
be used to generate a more refined pharmacophore model. In addition, it may be used to 
rationally design an MLS1547 analog that has improved G protein activation potency 
while maintaining signaling bias.  
 Thus far, studying the chemical scaffold of MLS1547 and the resulting 
pharmacophore model has been helpful in understanding G protein biased signaling of 
the D2R. It will also be important to test the receptor side of the pharmacophore model; 
in particular, interrogation of the residues hypothesized to be important for MLS1547 
binding and G protein bias. The hydrophobic moiety on MLS1547 is thought to interact 
with a binding pocket made up of the residues I184, F189, and V190. Likewise, the 
single nitrogen on ring D is thought to interact with T412. In future work, the D2R can be 
mutated at these residues and tested for G protein activation and β-arrestin-2 recruitment 
to see if this affects the signaling bias of the MLS1547 scaffold.  
 Notably, we found that in some cellular systems and assays, MLS1547 stimulated 
a low degree of D2R internalization (Figure 27 and Figure 28), but it is unclear whether 
this is due to arrestin-dependent or arrestin-independent mechanisms. Further studies are 
needed to determine the answer to this question. 
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 Overall, this dissertation attempts to increase the understanding of DAR signaling 
through studying events that arise from changes in GPCR conformation. While many 
advances have been made, there are many remaining avenues of study to better 
understand D1R-D2R cooperativity and D2R biased signaling. It is my hope that this 
dissertation provides a meaningful body of work that will lead to improved targeting of 
the D1R and D2R for the purposes of probing in vivo signaling as well as the treatment of 
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Development of structure-activity relationships for a G protein-biased agonist of the D2 dopamine 
receptor 
Experimental Biology 2015, Boston, MA 
Chun LS, Free RB, Vekariya RH, Beuming T, Shi L, Aubé J, Frankowski K, Sibley DR 
124 analogs of a D2R G protein-biased agonist (1547) were tested to develop structure-activity 
relationships (SAR). This SAR supported and refined a previously published molecular model for 1547 
binding to the D2R. 
 
Discovery and characterization of a G protein-biased agonist of the D2 dopamine receptor 
Experimental Biology 2014, San Diego, CA    
Chun LS, Free RB, Moritz AE, Conroy JL, Meade JA, Xiao J, Dulcey AE, Vekariya RH, Ferrer M, 
Javitch JA, Beuming T, Shi L, Southall N, Marugan JJ, Aubé J, Frankowski KJ, Sibley DR  
A high-throughput screen was conducted on a library of small molecule compounds for G protein-
biased D2 dopamine receptor signaling. A biased ligand was found, and signaling activity as well as 
molecular modeling were used to determine preliminary structure-activity relationships.  
 
Discovery and characterization of a G protein-biased agonist of the D2 dopamine receptor 
Graduate Research Symposium 2014, NIH, Bethesda, MD   
Chun LS, Free RB, Moritz AE, Conroy JL, Meade JA, Xiao J, Dulcey AE, Ferrer M, Javitch JA, 
Beuming T, Shi L, Southall N, Marugan JJ, Aubé J, Frankowski KJ, Sibley DR 
See above for description. Findings submitted to Molecular Pharmacology, and this poster was selected 
as one of eleven winners of the Graduate Student Research Awards. 
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Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment 
to the D2 dopamine receptor 
2013 GPCR Workshop, Maui, HI 
Free RB, Chun LS, Moritz AE, Miller B, Doyle TB, Conroy JL, Padron A, Meade JA, Xiao J, Hu X, 
Dulcey AE, Han Y, Duan L, Titus S, Bryant-Genevier M, Barnaeva E, Ferrer M, Javitch JA, Beuming 
T, Shi L, Southall N, Marugan JJ, Sibley DR 
See above for description.  
 
Discovery and characterization of a completely G-protein biased D2 dopamine receptor agonist 
Society for Neuroscience 2013, San Diego, CA  
Free RB, Chun LS, Conroy JL, Moritz AE, Miller B, Doyle TB, Padron A, Han Y, Southall N, Xiao J, 
Marugan JJ, Ferrer M, Javitch JA, Sibley DR 
See above for description.  
 
Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment 
to the D2 dopamine receptor 
American College of Neuropsychopharmacology 2013, Hollywood, FL 
Sibley DR, Free RB, Chun LS, Moritz AE, Miller B, Doyle TB, Conroy JL, Padron A, Meade JA, Xiao J, 
Han Y, Duan L, Ferrer M, Javitch JA, Southall N, Marugan JJ.  
See above for description.  
 
Investigation of the D1-D2 dopamine receptor heteromer reveals a complex signaling mechanism 
not limited to Gq protein activation 
Experimental Biology 2013, Boston, MA    
Chun LS, Free RB, Doyle TB, Huang XP, Sibley DR 
This poster presents data which implicates multiple contributing pathways affecting D1-D2 dopamine 
receptor heteromer signaling. Data also clarifies other mechanistic and pharmacological aspects of the 
heteromer.  
 
Investigation of the D1-D2 heteromer: pharmacology, subunit composition, and mechanisms of 
signaling 
10th Annual Catecholamine Symposium 2012, Pacific Grove, CA    
Chun LS, Free RB, Doyle TB, Huang XP, Sibley DR 
Invited to give an oral presentation. Data was shown which implicated multiple pathways involved in 
D1-D2 dopamine receptor heteromer signaling. The subunit composition as well as the pharmacology of 
the heteromer were also further elucidated. 
 
Both D2L and D2S dopamine receptor isoforms are able to form functional heteromeric complexes 
with the D1 dopamine receptor 
Society for Neuroscience 2011, Washington, DC    
Chun LS, Free RB, Doyle TB, Sibley DR 
This poster presents data on the pharmacology of the D1-D2 dopamine receptor heteromer, and the 
effects of various antagonists and agonists on the D1-D2S and D1-D2L dopamine receptor heteromer. 
 
Possible differences in signal transduction for the D1-D2L and D1-D2S dopamine receptor 
heteromers 
Graduate Research Symposium 2011, NIH, Bethesda, MD    
Chun LS, Free RB, Sibley DR 
This poster presents data on the pharmacology of the D1-D2 dopamine receptor heteromer, and the 
effects of various antagonists and agonists on the D1-D2S and D1-D2L dopamine receptor heteromer. 
 
Divergent neuroadaptations in noradrenergic signaling underlie resilience and vulnerability in an  
animal model of PTSD 
Society for Neuroscience 2008, Washington, DC    
Olson VG, Rockett H, Reh R, Redila V, Chun LS, Raskind M, McMillan PJ, Szot P 





Finding a gene for a new distal myopathy 
Summer Undergraduate Research Symposium 2006, University of Washington, Seattle, WA    
Chun LS, Raskind WH 
This presentation was on an independent research project, funded by the NASA Space Grant 
Consortium. It  
involved a genomic, linkage disequilibrium study of a family with a history co-inheritance of 
pancytopenia with distal myopathy via microsatellite haplotype analysis and BigDye sequencing.   
 
A transmission disequilibrium test of DCDC2 markers in dyslexia 
Undergraduate Research Symposium 2006, University of Washington, Seattle, WA    
Chun LS, Raskind WH 
Presented data on an investigation of several candidate genes that were believed to cause dyslexia. 
Responsibilities included sequencing and genotyping probands.  
 
Lack of association between DBH -1021CT and susceptibility to Parkinson's disease 
Undergraduate Research Symposium 2005, University of Washington, Seattle, WA    
Chun LS, Zabetian CP 
Participated by presenting a poster on the preliminary results regarding linkage between the DBH -1021 




 Techniques: Mammalian cell transfection, cell culture, compound screening, live cell-based 
BRET/FRET assays, PCR, Taqman genotyping, competition and saturation radioligand binding, 
molecular cloning, mouse behavioral tests, mouse dissection, confocal. 
 
Software: Microsoft Word, PowerPoint, and Excel; GraphPad PRISM; ImageJ. 
  
AWARDS AND HONORS 
 
  JHU-NIH Graduate Partnership Program IRTA fellow (2009 - Present) 
 ASPET Robert F. Furchgott Travel Award, $1000 for travel to EB 2015 
 ASPET Graduate Student Travel Award, $1000 for travel to EB 2014 
 NIH Graduate Student Research Symposium Competition Award, $1000 travel award (2014) 
 ASPET Steven E. Mayer Travel Award, $1000 for travel to EB 2013 
 International Society for Neurochemistry Catecholamine Research Travel Fellowship, $1000 
for travel to 10th Annual Catecholamine Symposium (2012) 
 Mary Gates Scholar 
 NASA Space Grant Consortium/Bill and Melinda Gates Research Endowment, $1800 (2006) 
 Robert C. Byrd Scholarship, $1500 per academic year (2003 - 2007) 
  
PROFESSIONAL SOCIETY MEMBERSHIPS 
 
  American Society for Pharmacology and Experimental Therapeutics, Graduate student member 
(2010 - 2015) 
 NIH Science Policy Discussion Group, Graduate student member and blog contributor (2014 - 
2015) 
 
 
